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Optimization of de novo 10-hydroxygeraniol production in Saccharomyces cerevisiae 
Meghan Davies 
Monoterpenes and their indole alkaloid derivates are plant secondary metabolites 
valuable to the pharmaceutical and industrial sectors for their bioactivities in humans, cats and 
insects. The biosynthetic pathway to strictosidine, the central monoterpene indole alkaloid 
scaffold, proceeds via an industrially relevant intermediate – nepetalactol. The oxidized 
counterpart of this monoterpene, nepetalactone, is known for its euphoric influence on cats but is 
also a potent insect repellent. Unfortunately, low in planta levels of these metabolites have 
resulted in high production costs and environmentally unfeasible cultivation strategies for an 
industrial product with mass market appeal. Engineering a high-producing nepetalactol or 
strictosidine yeast would benefit several commercial sectors, however recent studies attempting 
de novo strictosidine in S. cerevisiae only achieved trace titers (0.5 mg/L). Activity of geraniol-
10-hydroxylase, a cytochrome P450, was an identified bottleneck in nepetalactol/strictosidine 
production. This thesis presents the application of a combination of strategies aimed at 
overcoming the geraniol-10-hydroxylase bottleneck and improving titres of 10-hydroxygeraniol. 
Geraniol-10-hydroxylase and cytochrome P450 reductase variants were explored to increase 
enzyme efficiency, wherein several reductases were shown to beneficially influence 
hydroxylation activity.  We further demonstrated that a cytochrome P450-reductase fusion 
increased carbon flux towards 10-hydroxygeraniol by 1.7-fold. Accumulation of a heterologous 
metabolite, putatively identified as isopulegol, was observed, implying inefficient channeling of 
carbon into the heterologous pathway. Deletion of two native reductases, oye2 and oye3, resulted 
in a 4.6-fold increase in carbon channeled to 10-hydroxygeraniol, resulting in a final 
accumulation of 144 mg/L of 10-hydroxygeraniol. These pathway optimization steps will aid in 
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1.1 Monoterpene Indole Alkaloids (MIA) 
Monoterpene indole alkaloids (MIAs) are a diverse and structurally complex family of 
bioactive secondary metabolites ubiquitous among the Apocynaceae, Loganiaceae and 
Rubiaceae plant families - with certain species producing upwards of 100 different MIAs1. These 
metabolites have become industrially relevant over the past few decades for their potent 
pharmaceutical activities; particularly their analgesic, antimicrobial, anticancer and 
antispasmodic properties2. In 1958, Canadian chemists Robert Noble and Charles Beer isolated 
two such MIAs, vinblastine and vincristine, from the leaves of Catharanthus roseus3. These 
metabolites became pharmaceutically important for their anti-tumor properties involving the 
potent inhibition of microtubule assembly4,5. However, as with most secondary metabolites, in 
planta quantities are negligible and are often present as complex mixtures making isolation 
economically unviable. For instance, vinblastine and vincristine constitute approximately 0.01% 
and 0.003% dry plant weight (DW) respectively, with quantities greatly dependent on plant 
growth conditions4. These low titers can be attributed to the biological complexity of MIA 
biosynthesis. In the case of vinblastine, the biosynthetic pathway is composed of at least 35 
intermediates, 30 enzymes and 2 regulatory genes spread over several intra and inter cellular 
compartments6. This elaborate pathway is representative of most native MIA biochemical 
pathways. In addition, the majority of these biosynthetic routes are poorly characterized, as many 
steps remain to be elucidated7. The low natural abundance of the pharmaceutically important 
vinblastine and vincristine explains why C. roseus is one of the most extensively studied 
medicinal plants. This research on C. roseus identified a common metabolite, strictosidine, 
involved in all MIA synthesis6,8,9. All identified MIAs can be derived from various oxidative, 
substitution and rearrangement reactions of strictosidine10,11. Thus, any optimization strategies 
for MIA production involves optimizing the production of strictosidine and its precursors, one of 
which is nepetalactol (Figure 1).  
Nepetalactol is a monoterpene intermediate in the strictosidine biosynthetic pathway that 
is industrially relevant for its oxidized counterpart – nepetalactone (Figure 1 and 2A). 




















































Figure 1. Overview of MIA biosynthesis beginning with the synthesis of strictosidine from nepetalactol. 




catnip, where it is the biologically active ingredient in commercial catnip. The intoxication 
effects of this molecule on cats is well known, however it has also occupied a less well-known 
niche since the 1960’s as insect repellent. Nepetalactone is effective at repelling various species 
of insects, namely mosquitos, ticks, mites and cockroaches12–15.  It can be at least as effective a 
repellent as N,N-Diethyl-m-toluamide (DEET), which makes nepetalactone valuable given the 
growing population of DEET resistant mosquitoes16.  
1.2 Economics and production strategies of MIAs and nepetalactone 
1.2.1 Economic feasibility of MIA and nepetalactone production 
 Commercial production strategies for both nepetalactone and most MIAs rely heavily on 
the mass cultivation and extraction from the desired plant species. Generally, plants must reach 
maturity before the leaves are harvested and prepared for extraction17. With respect to MIAs, 
several direct extraction methods have been explored in attempts to increase extraction 
efficiency. These include ionic liquid ultrasound assisted extraction18, supercritical CO2 fluid 
extraction with methanol as a co-solvent (achieving 0.0466 mg vinblastine/g DW)19 and 
negative-pressure cavitation extraction (0.126 mg vinblastine/g DW)20. Though these optimized 
methods succeeded in increasing the extraction efficiency, in planta levels of MIAs are too low 
to be economically feasible for pharmaceutical interest. 
Given the biological importance of vinblastine and vincristine, MIAs may be an untapped 
source of pharmaceutically relevant molecules. However, many drug screening efforts exclude 
plant natural products in favor of screening larger numbers of simpler molecules, which can be 
produced inexpensively using chemical synthesis21,22.  The current capital needed to develop and 
bring a drug to market is around $0.8–1.7 billion, allocated to discovery (10%), preclinical 
(15%), manufacturing and processing (15%), clinical trials (55%) and post-marketing (5%)23. 
Taking the high failure rates of clinical development into consideration, currently estimated at 
94-96%, a high market potential is required for a big pharmaceutical company to be interested in 
any new product23. Although the chemical syntheses of plant natural products, particularly 
alkaloids, are improving24, MIAs pose too great of a financial risk where many syntheses are still 
too complicated or low yielding for drug discovery and commercial production, or require 











Figure 2. Structure and stereochemistry of nepetalactol and nepetalactone. 
A) The point of oxidation (red) for nepetalactol to nepetalactone. The numbers designate the position of the 4a and 





in an efficient and economically viable manner, the pharmaceutical potential of MIAs could be 
realized.  
Compared to MIAs, nepetalactone has a shorter biosynthetic pathway and higher in 
planta yields, though not high enough to meet growing demand. Currently, catnip production is 
centered in Western USA and Canada where the limited commercial crop area is dedicated to the 
production of essential oils or dry leaves for catnip toys and herbal uses25. The extraction of 
nepetalactone oil from high yielding plants hovers around 15 mg nepetalactones/g DW26. 
Depending on the plant species, this 15 mg can be composed of several stereoisomers produced 
by the 4a and 7a chiral centers (Figure 2B). Nepeta cataria is the most commonly cultivated 
species with three nepetalactone enantiomers present in its extracted oil, the predominant being 
(4aS,7S,7aR) (up to 90%) and (4aS,7S,7aS) (up to 78%)27. It has been observed that optimal 
insect repellency requires a specific 3:2 ratio of the (4aS,7S,7aR) and (4aS,7S,7aS) 
enantiomers12,28, while cats prefer the (4aS,7S,7aS) enantiomer27.  Keeping this ratio consistent, 
it was found that 23 ug/cm2 of body surface area is adequate for effective repellency of 
mosquitoes for up to 6 hours28. Assuming an average adult has a body surface area around 1.85 
m2 (160lbs, 170cm) and applies the repellant to half their body, it would require approximately 
213 mg of nepetalactones per 6 hours.   
A study conducted on a commercial herb farm in Richland, New Jersey found that the 
highest yielding crop of nepetalactone involved 80 724 plants/ha, resulting in 770 kg/ha DW 
from which 12.5 kg/ha of total essential oil was extracted25. Seventy-three percent of the 
extracted oil was attributed to (4aS,7S,7aR)-nepetalactone, totalling 9.13 kg/ha. Extrapolating to 
a per plant basis, this corresponds to approximately 113 mg of this enantiomer per plant. 
Returning to the assumption that one person requires 213 mg (of a 3:2 ratio) per 6 hours, this 
suggests that ~ 1 plant/person/day is required if an insect repellent is desired. In 2016, the 
mosquito repellent market size in North America alone was estimated at $969.6 million USD and 
is expected to reach $4.8 billion in 2022 coinciding with the rising threat of mosquito-borne 
diseases29–31. To this extent, the amount of land allocation required to sustain any reasonable 
demand of a nepetalactone based insect repellent would be unfeasible, with one hectare of land 
providing enough nepetalactone for around 2700 people for one month (assuming use is once 
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every day). Factoring in the amount of water to sustain the required crops32 further emphasizes 
the wastefulness and inefficiency of current strategies.  
The remainder of the section will focus on optimization strategies for MIA biosynthesis. 
To date, there have been no apparent attempts to optimize nepetalactone yields either through 
direct optimization of in vitro/in vivo methods or total chemical synthesis, further emphasizing 
the need to develop efficient production strategies.  
1.2.2 Optimization of C. roseus cell cultures for the production of MIAs 
The use of plant cell bioreactors is an attractive alternative to improve secondary 
metabolite formation, including MIA production. They provide favorable conditions in which 
several factors can be tested to boost MIA yields without environmental, ecological or climatic 
limitations and allow cells to proliferate at higher growth rates than whole plants in cultivation33. 
Such optimization methods include screening and selecting for high-producing cell lines, 
exogenously supplying specific pathway regulators or precursors, changing medium conditions 
or culture conditions such as light, temperature, and aeration6. A bench top bioreactor was 
designed for C. roseus plant cell cultures allowing continuous extraction of secondary 
metabolites. The addition of trans-cinnamic acid, an inhibitor of phenylalanine ammonia lyase 
activity34, paired with mannitol-induced osmotic stress increased the total alkaloid content to 
around 110 mg/L, an approximate 11-fold increase compared to the control35.  Although this is a 
substantial increase, it is for total alkaloid content and not specific to the valuable MIAs. 
Production of complex MIAs in C. roseus cultures is limited by the complexity of metabolic 
regulation involving intracellular compartmentation, several different cell types and tissue 
differentiation36. In terms of complex MIAs, UV-B irradiation of C. roseus cell cultures 
increased yields of the vinblastine precursors, vindoline and catharanthine (Figure 1) to 0.06 ± 
0.0023 and 0.12 ± 0.0054 mg/g DW corresponding to a 117- and 3-fold improvement over the 
control, respectively37. Even with minor improvements, MIA yields are still economically non-
viable thus driving the need to find better methods. 
1.2.3 Genetic modification of C. roseus 
Another potential method to increase MIA yields is through genetic modification of C. 
roseus. Transgenic C. roseus strains have been created in which MIA synthesizing or regulating 
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genes have been modified, including the overexpression of transcription factors and 
transporters38,39. The overexpression of the Orca3 transcription factor and the C. roseus geraniol-
10-hydroxylase (G10H) in leaf tissue increased yields to 2.13 ± 0.88 mg vindoline/g DW and 
4.57 ± 0.79 mg catharanthine/g DW, 3- and 2.3- fold improvements, respectively40. Recently, the 
overexpression of the C. roseus tryptophan decarboxylase (CrTDC) and strictosidine synthase 
(CrSTR) (Figure 1), two rate-limiting enzymes involved in strictosidine biosynthesis, in 
transformed leaf tissue increased vindoline and catharanthine content to 3.0 ± 0.3 and 1.0 ± 0.1 
mg/g DW respectively, with an approximate 6- and 2.5-fold increase compared to the control41. 
However, transgenic C. roseus lines are unstable, with the wildtype phenotype re-emerging after 
successive generations6.  While the direct over-expression of encoding genes has resulted in the 
improved accumulation of desired products, the overall low yields and the instability of genetic 
modifications highlight the need for better methods. 
1.2.4 Direct chemical synthesis of MIAs 
  As in planta genetic modification strategies for MIA production proved to be ineffective 
and non-robust, several semi-synthetic strategies were developed for MIA production. The more 
abundant and naturally occurring plant MIAs, vindoline and catharanthine, were extracted and 
coupled via chemical means to produce vinblastine following the oxidation of the 
anhydrovinblastine  intermediate42–45 (Figure 1). Initial protocols resulted in an overall yield of 
40-43% vinblastine, with a 20-23% loss to leurosidine, a vinblastine regioisomer45. While 
vindoline and catharanthine are more abundant than vinblastine, their yields are limited by plant 
production. Since this alternative semi-synthetic method relies heavily on limited natural sources 
of these secondary metabolites, full chemical synthesis of vindoline and catharanthine was 
investigated. Yokoshima et al.46 accomplished a stereo-controlled total synthesis of vinblastine 
via chemical derivation of both vindoline and a pseudo-catharanthine partner, involving 42 
intermediates (19 for vindoline, 21 for pseudo-catharanthine and 2 for their coupling) with an 
overall total conversion of less than one percent46,47. Though this is an impressive feat and a 
valuable starting point for optimized MIA production, overall yield was reported as “nearly 
quantitative” and synthesis was laborious requiring an extensive list of chemicals and conditions 
which would not be feasible to replicate at industrial scales48.  
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Overall, the current mass cultivation strategies for commercial production of both 
nepetalactol and high value MIAs are suboptimal. High costs and poor yield of plant and 
chemical synthesis have stimulated interests in developing alternative large-scale production 
processes. An attractive alternative is to reconstitute these pathways in a microbial host. As the 
substrates for microbial fermentation are renewable and most processes occur at 30-37˚C, 
biological production processes are economical and not energy intensive49–51. This provides a 
more scalable, robust and cost-efficient solution for MIA production. Furthermore, extensive 
metabolic engineering studies with Saccharomyces cerevisiae have demonstrated its potential to 
accumulate high titers of alkaloids and terpenes, with significant potential for improvement in 
yields10,52,61,53–60. To this effect, the introduction and optimization of a nepetalactol production 
platform in S. cerevisiae would benefit both MIA and nepetalactone production. 
1.3 Biosynthesis of nepetalactol and the global MIA precursor, strictosidine 
The identification of the MIA precursor biosynthetic pathway has enabled the 
heterologous production of strictosidine in S. cerevisiae57, establishing a potential production 
platform for MIA synthesis. This platform would also enable scalable and economically feasible 
production of nepetalactone. 
1.3.1 Precursor pathways 
The condensation of two isoprene units is responsible for initiating synthesis of the 
secologanin that, when condensed with tryptamine, forms the structural backbone strictosidine, 
the precursor to all MIAs11 (Figure 3). Whereas tryptamine is derived from the decarboxylation 
of tryptophan by TDC, secologanin is produced in a complex series of transformations which 
originate from isopentenyl pyrophosphate (IPP) and dimethylallyl pyrophosphate (DMAPP). 
Two distinct and independent biosynthetic routes exist for the formation of these 
pyrophosphates, the mevalonate-dependent (MVA) and the methylerythritol phosphate (or 1-
deoxyxylulose-5-phosphate) pathways. In eukaryotes, other than plants, these isoprenes originate 
from acetyl-CoA via the MVA pathway. Plants can use either the methylerythritol phosphate 
pathway, in which pyruvate is condensed with glyceraldehyde-3- phosphate62, or the MVA 
pathway. While monoterpenes have been suggested to result from the methylerythritol phosphate 
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pathway in planta63, yeast employs the MVA pathway, hence this route will be described in 
further detail.  
The MVA pathway is initiated with condensation of three molecules of acetyl CoA 
by acetoacetyl CoA thiolase (ACAT) and 3-hydroxy-3-methylglutaryl CoA (HMG-CoA) 
synthase (HMGS; Erg13) to yield the intermediate HMG-CoA, which is subsequently reduced to 
mevalonate by the rate-controlling enzyme HMG-CoA reductase (HMGR) in the first committed 
step of the pathway64–67 (Figure 3). HMGR is regulated through a multivalent feedback 
mechanism mediated by downstream sterol and non-sterol metabolites68,69, ensuring maintenance 
of lipid homeostasis by regulating the accumulation of HMG-CoA, which is known to inhibit 
fatty acid biosynthesis70,71. Two variants of HMGR exist in S. cerevisiae, Hmgr1 and Hmgr2, 
with 83% of enzyme activity attributed to Hmgr172,73. Mevalonate is then converted to 
melvalonate-5-phosphate following two  phosphorylation events catalyzed by mevalonate 
kinase (MVK; Erg12), which is feedback regulated by the downstream isoprenoids 
geranyl pyrophosphate (GPP) and farnesyl pyrophosphate (FPP)74,75. Melvalonate-5-phosphate is 
then phosphorylated and decarboxylated by phosphomevalonate kinase (PMVK; Erg8) and 
mevalonate pyrophosphate decarboxylase (MVD), respectively, to produce the basic isoprene 
building block for all terpenoids, IPP67,69. The isomerization of IPP to its highly electrophilic 
isomer, DMAPP, by isopentenyl diphosphate isomerase (IDI) represents the final step in the 
MVA pathway76 and is suggested to be rate-limited, thereby favouring IPP accumulation (Figure 
3)77,78.  
A head-to-tail condensation of IPP and DMAPP by farnesyl diphosphate synthase (FPPS; 
Erg20) produces GPP, the isoprenoid backbone involved in the synthesis of either monoterpenes, 
or sterols and quinones by further converting GPP to FPP79. While Erg20 in S. cerevisiae has 
both GPP and FPP synthase activity, GPP is not released from the catalytic site and is quickly 
converted to FPP, hence the lack of monoterpene accumulation in most yeast strains80. 
Conversely, plants have GPP synthases (GPPS) that exclusively produce GPP enabling 












































Figure 3. Overview of nepetalactone and strictosidine biosynthesis in engineered S. cerevisiae. 
The general biosynthetic pathway can be divided into three sections: 1) The MVA pathway (blue), native to S. 
cerevisae, which is responsible for producing the C5 isomer building blocks used to synthesize the monterpnene 
precursor, GPP. 2) Precursor synthesis (white) which involves GPP formation and production of the shikimate 
derived tryptamine. 3) Strictosidine biosynthesis (pink), heterlogous to S. cerevisiae, wherein a derivitized GPP 
condenses with the tryptmaine to produce strictosidine. The enzymes involved in optimizing 10HG production in an 
engineered S. cerevisiae strain are colored. Enzymes in blue denote the overexpression of the native yeast genes, 
those highlighted in red indicate a mutated native yeast enzyme and those in pink denote the expression of 





1.3.2 Strictosidine and nepetalactone formation in planta 
Synthesis of strictosidine in C. roseus involves nine enzymatic steps initiated by the 
dephosphorylation of GPP to geraniol by geraniol synthase (GES)85 (Figure 3). Hydroxylation of 
geraniol to 10-hydroxygeraniol (10HG) by G10H, a cytochrome P450 (CYP), and its CYP 
reductase (CPR) redox partner, define the first committed step towards iridoid 
monoterpenoids11,86. 10HG is oxidized by 10HG oxidoreductase (10HGO)87 to produce 10-
oxogeraniol which is subsequently cyclized by iridoid synthase (IS), an NADPH-dependant 
reductive cyclase88, to produce nepetalactol. Production of the nepetalactol intermediate marks a 
branch point from which nepetalactone biosynthesis can occur. In the Nepeta plant species, IS 
works with three nepetalactol-related short-chain reductases (NEPS) for the cyclisation of 10-
oxogeraniol to nepetalactol, determining the stereochemistry of the bridgehead 4a-7a-carbons89 
(Figure 2). IS catalyses the initial reduction of 10-oxogeraniol to the activated oxocitronellyl enol 
intermediate enabling spontaneous cyclisation to (4aS,7S,7aR)-nepetalactol. During spontaneous 
cyclisation, Neps1 and Neps2 have been demonstrated to stabilize the enol intermediate thereby 
reducing off-target iridodial products. Conversely, Neps3 can act on the enol intermediate 
catalysing its cyclisation to the (4aS,7S,7aS) enantiomer89. Subsequent oxidation by Neps1 is 
responsible for the conversion of the nepetalactol isomers to their cognate nepetalactone 
isomers89. In the continuation of strictosidine synthesis, a complex series of reactions involving 
three CYPs [iridoid oxidase (IO), 7-deoxyloganic acid hydroxylase (7DLH), and secologanin 
synthase (SLS)] converts nepetalactol to secologanin, via oxidative ring cleavage11. In the final 
steps, secologanin is condensed with tryptamine by STR to form strictosidine57,90 (Figure 3). The 
complete elucidation of the strictosidine biosynthesis pathway has enabled the heterologous 
production of strictosidine in S. cerevisiae. However, multiple points in the native and 
heterologous pathways have been identified that must be optimized for efficient in vivo 







1.4 Optimization of nepetalactol production in S. cerevisiae  
1.4.1 Optimization of native yeast pathways  
In vivo GPP accumulation 
In order to achieve high titers of strictosidine, the monoterpene biosynthetic pathway in 
S. cerevisiae must be upregulated to ensure high carbon flux to the precursor GPP. The available 
GPP precursor pool in S. cerevisiae is severely limited as it is produced as a tightly enzyme-
bound intermediate in the two-step synthesis of FPP (Figure 3). The sequestration of GPP to the 
enzymatic catalytic site explains why it is not released for the biosynthesis of C10 isoprenoids79. 
Unlike plants, microorganisms do not usually express a specific GPPS, with the exception of a 
few wine making yeast strains91. To overcome this issue, multiple mutants of the Erg20 protein 
have been characterized in S. cerevisiae, of which Erg20K197E specifically, partially disrupts the 
binding of GPP to the protein, allowing for GPP accumulation92–94. Introduction of the K197E 
mutation into wild type S. cerevisiae increased geraniol accumulation from 0.047 ± 0.017 mg/L 
to 4.2 ± 0.62 mg/L when paired with a plant GES59. Several others mutants have been 
characterized, displaying broad effects on monoterpene and sterol accumulation, and cell 
growth59,95. The additional incorporation of a heterologous plant GPPS in S. cerevisiae has also 
been demonstrated to further enhance GPP accumulation57,58. 
Overexpression of MVA pathway genes for increased precursor supply 
Increased production of monoterpenes requires an increased supply of precursors, namely 
GPP. This can be achieved by upregulating carbon flux through the MVA pathway in yeast. 
HMGR is the major late-limiting enzyme in the MVA pathway96. Several studies aimed at 
increasing the carbon flux through the MVA pathway for heterologous synthesis of plant 
secondary metabolites alleviated this bottleneck by the overexpression of all (or most) MVA 
genes in addition to one to three copies of a truncated Hmgr1 (tHmgr1)52,61,97,98. Since HMGR is 
an ER bound protein tightly controlled by transcriptional and degradational repression69, 
truncation of its N-terminal domain, which is responsible for the ER localization and regulation, 
circumvents the multivalent feedback mechanism in yeast, resulting in a soluble, degradation-
stabilized variant thereby increasing its activity61,98,99. 
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In addition to HMGR, IDI was also identified as a rate-limiting enzyme favoring the 
synthesis of IPP over DMAPP. The overexpression of IDI favors the first step of the Erg20 
reaction, ie. GPP formation, since under these conditions, DMAPP is more readily available for 
Erg20 catalysis, leading to a higher GPP/FPP ratio95. This study demonstrated that the 
overexpression of tHmgr1 and IDI was sufficient to overcome rate-limiting issues by obtaining a 
9-fold increase in geraniol titers (6.77 mg/L) when paired with wild type Erg20 and Ocimum 
basilicum GES (ObGES). Further introduction of a mutant Erg20 (Erg20K197G) resulted in a 50-
fold increase in geraniol, with titers reaching 36.04 mg/L77. 
Reducing off-target activity 
Accumulation of heterologous product is often hindered by the activity of native enzymes 
acting on the pathway intermediates. Geraniol and other strictosidine pathway intermediates are 
affected in such a manner by the Old Yellow Enzymes (OYE)100–104. Two OYE homologs are 
found in S. cerevisiae (Oye2 and Oye3), catalyzing a variety of flavin-dependent, stereospecific 
reductions of α,β-unsaturated double bonds105. There have been several studies that demonstrate 
Oye2 mediated reduction of geraniol to citronellol , as evidenced by a 60% increase in geraniol 
accumulation following Oye2 deletion, which was further corroborated by a 40% increase in 
citronellol following Oye2 overexpression100,101. In addition to Oye2, Oye3 is also implicated in 
direct α,β-unsaturated monoterpenol reduction, wherein a 44% reduction of side products was 
achieved from a strain lacking both OYE homologs, an improvement over the 33% reduction 
from Oye2 deletion alone102.  
1.4.2 Introduction and optimization of plant pathways 
Initial work towards optimizing the heterologous pathway in S. cerevisiae 
Several studies have focused on the heterologous optimization of specific enzymatic 
steps in the strictosidine pathway106,107, however, there have only been two studies to date that 
have succeeded in de novo production of either nepetalactol58 or strictosidine57 in S. cerevisiae. 
Based on these initial studies, several limiting steps were identified. Brown et al. were successful 
in producing trace amounts (0.5 mg/L) of strictosidine following the optimization of both native 
and heterologous pathways57. Their initial strain was built using the above strategies aimed at 
increasing precursor supply (ie. overexpression of tHgmr1, IDI and introduction of an Erg20 
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mutant) coupled with expressing all the required heterologous genes for strictosidine 
biosynthesis (Figure 3). When no strictosidine was detected in this strain, they supplied 
strictosidine pathway intermediates individually to the culture media, from which they identified 
either geraniol supply or G10H activity to be limiting. In terms of G10H activity, the expression 
of a second G10H enabled trace amounts (0.011 ± 0.002 mg/L) of strictosidine to be detected. In 
addition, minimizing geraniol metabolism to off-target products, the deletion of Oye2 and Atf1, 
an alcohol acetyltransferase (previously shown to act on geraniol100), similarly resulted in trace 
titers of strictosidine. To further increase geraniol supply, Adh2, an alcohol dehydrogenase 
responsible for the conversion of ethanol to acetaldehyde108 (the acetyl-CoA precursor), was 
overexpressed in the OYE deletion strain, increasing strictosidine to 0.017 ± 0.007 mg/L. The 
amalgamation of these strategies along with an additional three G10H copies (total of 5) resulted 
in the production of 0.5 mg/L strictosidine57. Poor G10H activity was suggested to be the main 
culprit for limiting strictosidine yields in engineered S. cerevisiae.  
Campbell et al. further demonstrated that the low titers due to poor G10H activity is 
further aggravated by the promiscuous activity of IS using the pathway intermediates geraniol 
and 10HG as substrates, in addition to 10-oxogeraniol58. IS reduces geraniol and 10HG to non-
productive pathway intermediates citronellol and 10-hydroxygcitronellol, respectively58. The 
promiscuous activity of IS was further corroborated by Billingsley et al. who demonstrated that 
exogenously supplied 10HG was converted, almost exclusively (90%), to 10-
hydroxytetrahydrogeraniol in an S. cerevisiae strain harboring only 10HGO and IS102. Two 
distinct, non-productive pathways were identified where 10HG and 10-oxogeraniol were 
substrates for 1) ‘ene’-reduction and 2) reduction by iridoid synthase in a non-productive redox 
cascade involving yeast alcohol and aldehyde dehydrogenases102. With respect to the first non-
productive pathway, both Oye2 and Oye3 individually paired with 10HGO reduced 10-
oxogeraniol to 10-hydroxytetrahydrogeraniol. The individual knockout of Oye2 and Oye3 
decreased 10-hydroxytetrahydrogeraniol accumulation by 33% and 44% respectively, with a 
99% reduction observed for their combined knockout.  For the second non-productive pathway, 
endogenous yeast dehydrogenases were demonstrated to work with IS wherein Ari1, Adh6, and 
Adh7 were found to influence 10-hydroxytetrahydrogeraniol production, with their combined 
deletion causing a 169% increase in nepetalactol in the OYE deletion background strain102.  
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The specific activity of IS was further investigated following the elucidation of its crystal 
structure in complex with NADP+/8-oxogeranial107. Ninety-five single-site point mutations were 
individually introduced into the substrate binding pocket, as well as the extra cavity of IS, to 
assess the catalytic mechanism and substrate specificity. These mutations resulted in a broad 
spectrum of IS catalytic activity on 10-oxogeraniol with activities ranging from <5% to 100% of 
the wild type enzyme activity, with only 25 of the 95 mutants retaining at least 65% activity107. 
These results implicated a non-conserved hydrophilic Ser349 residue and the hydrophobic 
scaffold at the substrate binding pocket to be determinant of substrate specificity. To this extent, 
certain point mutations may be capable of mitigating IS promiscuity, however since only 10-
oxogeraniol was tested as a substrate, further research will need to assess the activities of the 
mutant library on other substrates.  
With these previous studies in mind, several optimization strategies can be employed in 
S. cerevisiae that can build off this previous work to further optimize nepetalactol and 
strictosidine production. As poor G10H activity was implicated in several of these studies and 
was identified as a major bottleneck, several strategies can be explored to further increase 
geraniol supply and optimize geraniol hydroxylation activity.  
Modifying GES for optimal expression in S. cerevisiae  
Though endogenous yeast enzyme activity can reduce GPP to geraniol, specific plant 
monoterpene synthases are more suitable for the efficient and specific conversion of GPP to 
geraniol. In planta, GES is localized to the plastid via a targeting peptide at the N-terminus 
which is cleaved upon insertion into the organelle, forming the mature protein. The expression of 
this signal peptide in S. cerevisiae has been suggested to interfere with enzyme activity, as 
removal of this targeting sequence increases enzyme functionality106,109.  The introduction of a 
truncated Valeriana officinalis GES (tVoGES) into wild type S. cerevisiae yielded 2.7 mg/L of 
geraniol, an approximate 3.4-fold increase compared to the full length VoGES. Pairing the 
tVoGES with the overexpression of tHmgr1 and IDI increased geraniol titers to 7.9 mg/L, with 





Potential ways to optimize G10H activity 
As demonstrated by Brown et al.57, G10H remains a major limiting step in nepetalactol 
and strictosidine biosynthesis, wherein no current optimization strategies have been attempted. 
G10H is a monooxygenase belonging to the extensive CYP superfamily of hemoproteins. This 
cytosol-facing, N-terminally bound ER protein catalyzes the C10-hydroxylation of geraniol, 
requiring the transfer of two electrons catalyzed by the ER bound, NADPH-dependent CPR110–
114. Several studies have identified factors affecting heterologous CYP expression in yeast such 
as CYP:CPR ratio, CPR choice and protein localization. As alluded by the multiple CYP copies 
required in the work by Brown et al.57, optimal CYP:CPR ratios, which exist in nature, can be 
upwards of 15:1115,116. For example, Biggs et al. optimized heterologous production of the Taxol 
precursors, oxygenated taxanes, by increasing the CYP:CPR ratio to 12:1, achieving the highest 
reported titers of oxygenated taxanes (570 ± 45 mg/L)116. This high ratio may ensure a type of 
logistic control required for efficient electron transfer from the CPR to the CYPs117. In addition, 
CPRs can both generate and deplete reactive oxygen species on their own merit, this low CPR 
ratio may impede this energetically wasteful process118. Increasing CYP copy number likely 
mimics the optimal conditions found in nature.  
This intricate relationship is further demonstrated by the high evolutionary conservation 
of the CYP and CPR interaction domains, where pairs from different species or kingdoms have 
the ability to alter, influence or compliment enzyme functionality117,119–122. Furthermore, CPR 
sharing is not uncommon, wherein multiple CYPs receive electrons from a single CPR donor. 
This is exemplified in plants, in which one to three CPR paralogs are the sole providers of 
electrons for all CYP reactions117. Although S. cerevisiae expresses a native CPR, heterologous 
expression of plant CYPs can offer higher activity upon co-expression of a plant CPR. For 
instance, co-expression of the Coleus blumei CYP (CbCYP) with its cognate CPR in yeast 
increased the enzymes’ hydroxylation activity up to 7-fold over the endogenous yeast CPR123 . 
The observed activity of CbCYP in the presence of the native yeast CPR alone demonstrates 
CYP/CPR functionality across kingdoms, however, the increased activity in the presence of a 
plant CPR may suggest a more productive relationship between enzyme partners within the same 
kingdom. More recently, a study combinatorially tested various plant CYP-CPR pairs for their 
effect on steviol biosynthesis in S. cerevisiae119. Their expression system assessed the sequential 
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oxidation and hydroxylation of kaurene by two individual CYPs, kaurene oxidase (KO) and 
kaurenoic acid hydroxylase (KAH), from two plant species (Stevia rubaudiana (Sr) and an 
unnamed species) paired with various CPRs on steviol biosynthesis. Despite only certain KO 
variants from both species displaying marginally higher activity in the presences of a plant CPR 
compared to the endogenous yeast CPR, all KAHs were generally more productive with the co-
expression of plant CPRs. In addition, both the KO and KAH from the unnamed species 
outperformed the SrKO and SrKAH when paired with the SrCPR by 10% and 30% respectively. 
These results corroborate the observed increase in activity for CbCYP in the presence of a plant 
CPR and further expand on the potential of enzyme pairs from different species to influence 
catalytic functionality.  Additionally, their final steviol strain harbored a 2:1:1 ratio of 
KO:KAH:CPR, reinforcing the necessity to optimize CYP:CPR ratios119.  
Another critical element for of CYP-CPR function is proper ER localization, mediated by 
ER-targeting N-termini, which is required to maintain CYP-CPR proximity for efficient electron 
transfer113,124,125. Functional heterologous expression of plant CYPs in yeast cells may be 
influenced by their N-terminal anchor sequence. Previous studies have shown that, when 
heterologously expressed, a non-functional CYP can gain activity if its N-terminus is exchanged 
with one from a CYP shown to be functionally expressed in S. cerevisiae124,126. Larbat et al. were 
able to characterize monooxygenase activity from their plant CYP, psoralen synthase, in S. 
cerevisiae following the exchange of its N-terminus for that of a functionally active CYP124. 
Prior to the swap, no monooxygenase activity was detected, presumed to be caused by 
insufficient membrane association, or to low translational efficiency caused by an unfavorable 
codon bias on yeast expression124.  However, exchange of the N-terminus for that of  a cinnamate 
4-monooxygenase, shown to be expressed in yeast127,  allowed for initial characterization of 
substrate specificity and enzyme kinetics.  
Furthermore, in eukaryotic systems, CYPs and CPRs are their own entity both 
independently localizing and inserting into the membrane via their N-termini. However, an 
increasing number of bacterial CYP–CPR fusion enzymes have been identified in nature such as 
the fusion CYP-CPR (BM3) isolated from Bacillus megaterium displaying the highest reported 
monooxygenase activity for a CYP enzyme128,129. Since their discovery, a large number of CYP–
CPR fusion enzymes have been created by genetic engineering128. Artificial fusions of 
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eukaryotic CYP-CPR enzymes can produce efficient, catalytically self-sufficient entities. The 
proximity of the reductase to the CYP could enhance the frequency of productive interactions, 
hence increase the electron transfer and overall turnover rates of the engineered CYP system128. 
Using BM3 as an architectural example, Leonard et al. improved the low turnover rate of their 
heterologously expressed plant CYP, amassing a 20-fold increase in isoflavone synthesis, 
demonstrating the importance of domain interaction between the cytochrome P450 and its redox 
partner protein130. Although the CYP-CPR fusion is juxtaposed by the high CYP to CPR ratios 
generally found in nature, a fusion may alleviate the issue with 1:1 ratio by decreasing off-target 
CPR reactions. 
1.5 Strategy for optimizing 10HG production in S. cerevisiae 
Nepetalactol production in S. cerevisiae would be a large step towards the efficient 
production of both nepetalactone and strictosidine, ultimately enabling the production of a wide 
array of high value MIA compounds. Previously, both 10HGO102 and IS107 activities have been 
investigated and scrutinized for optimizing in vivo nepetalactol production in S. cerevisiae, the 
final step requiring improvement is the C10 hydroxylation of geraniol by G10H.  
I hypothesized that the optimization of G10H activity via enzyme variant assessment and 
catalytic efficiency adjustments, coupled with mitigating off-target reactions would increase 
substrate turnover, thereby improving 10HG production. The optimization strategies first 
involved the production of the monoterpene geraniol using a combination of MVA enzyme 
overexpressions in a strain harboring an Erg20K197E mutation. Next, a G10H enzyme variant 
library, followed by modification of their N-terminus was assessed for their geraniol 
hydroxylation activity. Furthermore, the expression of various non-cognate CPRs was 
characterized for their ability to modulate 10HG activity. I also assessed the negative effect of 
promiscuous native S. cerevisiae enzymes on heterologous product accumulation. This 





2. MATERIALS AND METHODS 
2.1 Strains and media 
All S. cerevisiae strains built in this study are listed in Appendix Table A1. Yeast cultures 
were grown at 30°C with shaking at 200 rpm in YPD (10 g/L yeast extract, 20 g/L tryptone, 20 
g/L dextrose (Thermo Fisher Scientific)) or synthetic complete (SC) medium made with 6.8 g/L 
Yeast Nitrogen Base (YNB) with amino acids and supplemented with 2% glucose. To maintain 
selection for the Erg20K197E background, strains were under constant selection with 200 μg/ml 
geneticin (G418) (Sigma Aldrich). When appropriate 200 μg/ml of hygromycin was added for 
the selection of the pCas plasmid.  All plasmids used in this study are listened in Appendix Table 
A2 and were maintained and propagated in Escherichia coli DH5α. E. coli cultures were grown 
at 37°C with shaking at 200 rpm in Lysogeny Broth (LB) (Sigma Aldrich) supplemented with 
either 100 μg/mL of ampicillin or 100 μg/mL of hygromycin. 
2.2 DNA manipulation 
2.2.1 Plasmids and genes 
All genes and primers used in this study are described in Appendix Table A3 and 
Appendix Tables A4-A10 respectively. Promoters, terminators and the yeast MVA genes, IDI 
and truncated Hmgr1 (tHmg1), were amplified from S. cerevisiae CEN.PK genomic DNA. 
Genes originating from plant species, apart from the G10H variant library, were amplified from 
pYES2-GerOH58. The pCas plasmid used in this study was previously modified from the 
Addgene (plasmid #60847) in which the G418 resistance KanMX cassette was exchange for an 
hphNT1 cassette to confer hygromycin resistance (pCAS-Hyg). G10H variants were codon 
optimized and synthesized by GeneArt (Thermo Fisher Scientific) whereas the codon optimized 
PkCPR and VvCPR were synthesized by Twist Bioscience. These genes were further sub-cloned 
individually into pJet2.1 using the CloneJET PCR cloning kit (Thermo Fisher Scientific) and 
transformed into E. coli. Plasmids were purified from E. coli stocks using the GeneJET plasmid 
mini prep kit (Thermo Fisher Scientific) where the DNA parts were amplified by PCR using 
Phusion High-Fidelity DNA polymerase (Thermo Fisher Scientific), resolved using 0.8% (w/v) 




2.2.2 Gene library phylogenetic analysis 
 
The G10H gene library to be used in this study was selected using the CrG10H amino 
acid sequence as the search query for three separate databases: Plant Metabolic Network131, 1k 
Plant Collection132 and NCBI using DeltaBLAST133. From each database, sequences with over 
65% homology were selected. This list was consolidated using CD-HIT134 with a sequence 
identity cut-off of 90%. Bootstrapped (500 replicates) maximum likelihood phylogenetic trees 
for the G10H and CPR libraries were built (default settings) following MUSCLE alignment 
(default settings) using MEGA7135. The phylogenetic trees were rooted using the various 
outgroups, amino acid sequences can be found in Appendix Table A3.  
2.2.3 Gene modifications 
The N-terminal signal peptide of GES was identified using ChloroP 1.1 software136 
which predicts the chloroplast transit peptide and its possible cleavage site. Following 
identification, a truncated version was generated by PCR using primers listed in Appendix Table 
A5. The N-termini of the G10H and CPR variants were identified using the TMHMM server137. 
The desired N-terminus and truncated G10Hs were individually amplified using primers describe 
in Appendix Table A7 that added overlapping sequences to the 3’ end of the N-terminus and the 
5’ end of the tG10H (Figure 4). The two parts were then assembled by sequence overlap 
extension (SOE) PCR to generate the final chimera product. The CYP-CPR fusion was similarly 
assembled using primers from Appendix Table A9 that insert overlapping sequences containing 
the GST linker sequence and then assembled by SOE PCR. 
2.2.4 Linearization of pCAS and gRNA design 
For CRISPR-Cas9 directed gene modification or insertion, a 20 nucleotide guide RNA 
(gRNA) sequence targets the CRISPR-associated protein, Cas9, to a genomic specific loci where 
its endonuclease activity introduces a double stranded break138. By supplying an exogenous 
DNA fragment with regions of homology flanking the double-stranded break, yeast homologous 
recombination can initiate homology-directed repair, resulting in the integration of the desired 




The pCas-Hyg plasmid was isolated from E. coli and linearized following a double digest 
with BglI and BglII restriction enzymes (NEB). Synthetic gRNA targeting sequences (N20) 
towards previously characterized genomic loci141,142 were generated with a minimum GC content 
of 40% and queried against the S. cerevisiae genome to ensure the target sites were unique143. 
The gRNA expression cassette was amplified in two individual parts using the pCas vector 
backbone as a template and primers that insert overlapping sequences containing the novel N20 
gRNA target sequence (Appendix Table A4). These two parts were then assembled by SOE PCR 
to generate the final gRNA expression cassette. 
2.3 Yeast transformation and CRISPR/Cas9-mediated genome integration 
S. cerevisiae strains were transformed using a method modified from the Gietz PEG/LiAc 
protocol144 and were genetically modified using the CRISPR-Cas9 system138,145. Strains were 
initially grown overnight in YPD + G418 medium. The strains were then diluted to an optical 
density (OD600) of 0.05 and grown to a final OD600 of 0.6 to 0.8.  Two mL of culture per 
transformation was harvested and washed initially in sterile water and then in 100 µM lithium 
acetate.  The cell pellet was then suspended in 3M lithium acetate (5.6 μL per transformation) 
and DNA + water (total volume of 40 μL) and incubated at room temperature for 10 minutes 
before adding the transformation mix, which included per reaction: 100 µL 50% (w/v) PEG3350 
and 5 μL boiled salmon sperm DNA (10 mg/mL). Transformation conditions included a 15-
minute incubation period at 30°C, followed by a 30 minute heat shock at 42°C. The cells were 
recovered in 500 μL of YPD before plating on selective medium contain hygromycin and G418 
to maintain the pCas plasmid and select for the Erg20K197E genotype.  
DNA present in the transformation reactions included: linearized pCas vector backbone 
harboring cas9 (300ng), the gRNA expression cassette (600ng) and the donor DNA (1-4 μg) with 
homology to the desired integration site. In certain instances, UP and DOWN regions targeting 
adjacent genomic regions to the desired integration site were included, providing extra ~ 400 bp 
homology regions to the donor DNA. The UP and DOWN regions were amplified from S. 
cerevisiae CEN.PK genomic DNA using primers described in Supplemental Table S10. These 









Figure 4. Design of the N-terminal exchange for the G10H variants. 
The N-termini were exhanged to assess their infuence on G10H activity. The strategy employed in this experiment 
was as follows: A) The transmembrane regions were identified using TMHMM server where the probability of 
luminal (orange), transmembrane (TM, blue) and cytoplasmic (grey) domains were assessed. B) Following TM 
identfication, the N-termini and truncated G10Hs were individually amplified with specific primers that added 







These linkers are complimentary to the PCR added LV3 and LV5 linkers flanking the donor 
DNA. 
2.4 Colony PCR 
Individual colonies were suspended in 40 μL of sterile water. Twenty μL of the 
suspended colony was heated in a microwave oven for two minutes, from which 1.5 μL was used 
as template for a 5 μL colony PCR using Phire™ Plant Direct PCR Master Mix (Thermo Fisher 
Scientific). Primers used for the colony PCR were site specific and annealed to genomic DNA 
adjacent to the integration site. PCR products showing positive integrations were identified by 
agarose gel electrophoresis.  
2.5 Microscopy 
Cells were grown overnight at 30°C in SC media, reinoculated at a 1/10 dilution and 
incubated at 30°C for 4 hours. Log phase cells were then imaged on a Zeiss Axioplan 
microscope equipped with an Infinity 3 camera and a Ph3 Plan-NEOFLUAR 100x/1.30 Oil 
objective using Infinity Capture Software. All images were acquired using either a 750ms or 
900ms exposure and evenly processed in Adobe Photoshop CC.  
2.6 Analysis of Monoterpenes (GC-MS) 
 To analyze monoterpene production, metabolites from cultures of the various 
recombinant yeast strains were analyzed by GC-MSD.  Strains were inoculated in triplicate to an 
OD600 of 0.05 in a 96-well deep well plate containing 500 μL of YPD + G418 medium and 
incubated at 30°C and 200 rpm shaking for either 24, 48 or 72 hours. For sample preparation, 
400 μL culture aliquots were transferred to a new 96-well deep well plate and were extracted into 
0.5 volumes of ethyl acetate containing 10 mg/L of eugenol (Sigma Aldrich) as an internal 
standard. Extracts were analyzed by GC-EI-MS using an Agilent 6890N GC system coupled to 
an Agilent 5875C mass selective detector. Separation, following splitless injection, of 1 μL of 
extract was carried using an HP-5ms column (30 m ×0.25 mm × 0.25 μm film thickness) and 
hydrogen gas as the carrier with a constant flow of 1.3 mL/min and an inlet temperature of 
240°C. Separation conditions were as follows: initial oven temperature set to 60°C for 2 minutes, 
then an increase to 150 at 30°C/min, then increase to 220 at 10 °C/min and then a final increase 
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to 325 at 30°C/min (hold for 5 min). For monoterpene quantification, the Total Ion 
Chromatogram (TIC) for the positive ion electron-impact spectra at 70 eV was recorded in the 
scan range m/z 50–220 and Selective Ion Monitoring (SIM) monitored ions 67, 71 and 91 m/z. 
Total amount of citronellol, geraniol, eugenol and 10HG were determined using calibration 
curves with a minimum R2 value 0.98 over the concentration range of 3.90 to 1000 μM. 
Isopulegol was identified using the NIST 08 standard reference database147.  
 
3. RESULTS 
3.1 Increasing in vivo geraniol titers 
All titers reported in this thesis are normalized to the yeast culture OD600 of 1, unless 
indicated otherwise. The synthesis of 10HG in S. cerevisiae requires the modification of 
endogenous pathways to enable in vivo production of geraniol. S. cerevisiae does not naturally 
accumulate sufficient monoterpene precursor for geraniol production (ie. GPP), hence the 
modification of the native mevalonate pathway in conjunction with the expression of exogenous 
plant derived genes is essential for increasing GPP, and subsequently geraniol concentrations. 
Previously Campbell et al. introduced the Erg20K197E mutation59 into wild type CEN.PK (denoted 
strain MD1) to allow for in vivo GPP production58. This strain was used as the foundation for all 
further strain modifications reported in this present study. GPP is synthesized from two isoprene 
units that are derived from the mevalonate pathway where carbon flux is limited by ScHMGR 
and ScIDI. To this effect, a second copy of tScHmgr1 and ScIDI were integrated into the genome 
to overexpress the MEV pathway, as previously described77, resulting in strain MD2 which 
accrued trace titers of geraniol (0.07 ± 0.04 mg/L/OD600) (Figure 5A).  Once the isoprenoid 
precursor supply was increased, ObGES was integrated into strain MD2 leading to the 
accumulation of 1.26 ± 0.60 mg/L/OD600 in strain MD3. In planta, GES is localized to the 
plastids via a N-terminal targeting peptide that can interfere with enzyme activity when 
expressed in S. cerevisiae106. Exclusion of the predicted signal peptide from ObGES increased 
geraniol yields in strain MD4 by approximately 3.8-fold, accumulating 4.81 ± 0.52 mg/L/OD600 
of geraniol. The integration of the Abies grandis GPPS (AgGPPS) into MD4 further increased 
geraniol titers by over 2-fold, resulting in strain MD5 and titers of 10.79 ± 0.70 mg/L/OD600 







Figure 5. Geraniol titers of engineered S. cerevisiae and its influence on strain growth. 
A) Citronellol (grey), geraniol (blue) and OD600 values (•) of engineered strains. Error bars represent the standard 
deviation from triplicate cultures. B) Comparison of growth profiles for the geraniol production strains. Dotted lines 
correspond to the standard deviation for quadruplicate cultures. C) Specific growth rate (µmax) for engineered 
strains from quadruplicate cultures. Asterisk indicates statistically significant (p<0.05) growth rate compared to the 
wild type strain as determined by Student’s two-sample t-test assuming unequal variances with two tailed 
distribution. For A, B and C strain designation is as follows: WT (—); MD1, WT + ScErg20K197E (—); MD2, MD1 
+ tScHMGR + ScIDI (—); MD3, MD2 + ObGES; MD4, MD2 + t63ObGES (—); MD5, MD4 + GPPS (—). 
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48 hours (Appendix Figure 5A). For each round of integrations, citronellol titers were quantified 
to observe the extent of carbon loss in the form of non-productive reductions. In MD5, a 4.7 
percent molar loss of carbon in the form of citronellol was observed, corresponding with 0.54 ± 
0.03 mg/L/OD600 citronellol titers. 
 An inverse relationship between cell growth and increasing geraniol titer was observed in 
these strains with each subsequent round of integrations aimed at increasing geraniol titers 
(Figure 5A and B). The most notable effect on cell growth can be observed between the wild 
type CEN.PK strain and MD1, following the introduction of the Erg20K197E mutation. Due to the 
involvement of the FPP synthase activity of Erg20 in sterol and ubiquinone biosynthesis, it is 
presumed that decreasing the carbon flux towards these essential pathways will negatively affect 
cell growth. This effect is shown by a prolonged lag phase followed by a decrease in specific 
growth rate (µmax) from 0.49 ± 0.00 h-1 to 0.29 ± 0.00 h-1 between the wild type and MD1, 
respectively (p<0.05) (Figure 5B and C). This impaired growth is further shown by the lower 
growth yields for MD1 compared to wild type. A yeast culture with an OD600 of 1 has an average 
of 3.0 x 107 cells/mL, the introduction of the Erg20K197E mutation decreased growth yields from 
5.1 x 107 cells/mL to 3.8 x 107 cells/mL at 72 hours (Figure 5B). Moreover, a further decrease in 
cell growth occurs with each consecutive integration aimed at increasing geraniol titers. Though 
not significant (p>0.05), a decrease in growth rate is observed following GES expression (MD4) 
(Figure 5C). Longer lag phases and lower growth yields similarly coincide with increased 
geraniol titers, where strain MD4 accumulates 2.9 x 107 cells/mL at 72 hours, a 57 percent 
decrease compared to wild type (Figure 5B).  
3.2 Testing G10H variant library for geraniol hydroxylation 
Efficient de novo synthesis of 10HG in S. cerevisiae for nepetalactol and strictosidine 
biosynthesis requires optimizing the rate-limiting hydroxylation of geraniol by G10H. With the 
Catharanthus roseus G10H (CrG10H) being the only functionally characterized G10H to date, 
initial strategies to optimize this hydroxylation step involved testing other potential G10Hs for 
improved activity. Using the CrG10H amino acid sequence as the search query, a preliminary list 
of predicted G10Hs was established using three separate databases: Plant Metabolic Network131, 
1k Plant Collection132 and NCBI using DeltaBLAST133. Since G10H is a cytochrome P450 
(CYP, CYP76b6), the initial search results were extensive owing to the vast sequence diversity 
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of CYP families. Fifty-five percent sequence identity is sufficient for CYPs to belong to the same 
subfamily148. For the purpose of reducing the list to a more manageable number, sequences with 
over 65 percent homology were kept. This list was further consolidated to 269 sequences using 
CD-HIT134 to minimize redundancy among the sequences with a maximum percent identity set 
to 90 percent (Appendix Figure A1). This dictates that when there is a cluster of sequences with 
over 90 percent identity, the sequence that best represents the clade is kept and the rest are 
discarded. From the condensed preliminary phylogenetic tree, 15 sequences were chosen and 
verified for the presence of the CYP conserved domains (Figure 6A, Appendix Figure A2). This 
final list included three sequences isolated from plants known to produce 10HG (red), two of 
which have already been identified as G10Hs based on plant transcriptomics (PkG10H149 and 
GriG10H150), and two isolated from plant species known to produce geraniol (blue). The 
remaining sequences were isolated from plant species from which there is no prior knowledge of 
geraniol or 10HG production (Figure 6A). 
 To test the activity of these predicted G10Hs, a CYP reductase (CPR) is required to 
donate two electrons to catalyze hydroxylation. Accordingly, the C. roseus CPR (CrCPR) was 
previously integrated alongside GPPS in the making of strain MD5. Each of the predicted 
G10Hs was then individually integrated into MD5 and 10HG production was analysed by GC-
MS. Analysis showed that CrG10H remained the highest producer of 10HG with titers reaching 
2.22 ± 0.24 mg/L/OD600 (Figure 6B) following trace amounts observed from GrG10H (0.18 ± 
0.04 mg/L/OD600) and InG10H (0.13 ± 0.03 mg/L/OD600). However, InG10H was plagued with 
instability between consecutive rounds of analysis wherein varying amounts of geraniol and 
10HG were observed and was therefore discarded from further analysis. The majority of strains 
displayed a reduction in geraniol titers compared to MD5, suggesting geraniol is being used as a 
substrate, yet the lack of 10HG accumulation may imply the enzymes are involved in a non-C10 
hydroxylation reaction. StG10H and PpG10H achieved the most notable loss of geraniol titers, 
showing a near complete reduction. In all instances, the GC-MS chromatograms did not show the 
appearance of any new product peak. Similar to InG10H, EgG10H showed a sporadic loss or 
gain of geraniol between subsequent rounds of analysis and was discarded from further analysis 
(Figure 6B). The lack of geraniol hydroxylation activities from the predicted G10H library 






Figure 6. Monoterpene production in engineered S. cerevisiae strains harboring G10H variants. 
A) A bootstrapped maximum likelihood phylogenetic tree of predicted/putative G10Hs, rooted using the various 
outgroups. Certain variants were identified from plant species known to produce geraniol (blue) or 10HG (red). The 
remaining variants belong to plant species wherein the plant oil content has not been characterized. Certain variants 
have been characterized as a putative G10H (*) whereas others have been functionally characterized (**).  B) 
Monoterpene production of the G10H variants in the MD5 background strain. Geraniol (grey) and 10HG (red). Error 




3.3 N-terminal exchange of G10H variants 
As the initial screening of the G10H variant library did not identifying any candidate 
enzymes with improved activity over CrG10H, we pursued the targeted modification of CYP 
domains. CYPs are N-terminally bound to the ER which is important for functional 
expression113,124,125. Proper ER localization is essential due to the required proximity to the ER 
bound CPR. Replacing the N-terminus of a functionally impaired CYP for an N-terminus of a 
CYP shown to have activity in S. cerevisiae can stabilize expression124,126. Since CrG10H shows 
geraniol hydroxylation activity in S. cerevisiae, its N-terminus was used to replace the N-termini 
of the predicted G10Hs. Using TMHMM prediction software137, the transmembrane domains of 
all the G10Hs were annotated and the new chimeras were designed and assembled (Figure 4).  
As a control, the CrG10H N-terminus was exchanged for that of StG10H which had no 
observable in vivo geraniol C10 hydroxylation activity.  
A marginal change was observed in 10HG titers between the wild type CrG10H (4.28 ± 
0.63 mg/L/OD600) and the StG10H(Nt)CrG10H chimera (3.26 ± 0.44 mg/L/OD600) (Figure 7), 
suggesting the N-terminus of StG10H is not interfering with its expression and is capable of 
localizing to the ER. This hypothesis can be corroborated by microscopy data wherein GFP 
tagged versions of both proteins are seen to localize to the ER (Figure 8). It is worth noting the 
difference in 10HG titers for the CrG10H strain between Figure 6B and Figure 7, which may be 
attributed to slight differences in culture growth between experiments. Interestingly, the relative 
signal intensity from StG10H(Nt)CrG10H-GFP displays a lower expression profile compared to 
CrG10H-GFP, contrasting the GC-MS data showing similar 10HG titers. This may indicate an 
increased substrate turnover for the chimera or increased coupling efficiencies with the CPR 
since lower protein levels achieve similar titers. Furthermore, the StG10H(Nt)CrG10H chimera 
displays lower levels of geraniol accumulation (0.62 ± 0.05 mg/L/OD600) compared to the 
CrG10H strain (6.05 ± 0.54 mg/L/OD600). These geraniol levels observed for the chimera seem 
to remain relatively consistent with the wild type StG10H (Figure 6B and 7). However, this 
result is not consistent among chimeras, where the CrG10H N-terminus seems to alter geraniol 
titers in most of the G10H variants.  
In addition to the activity observed from the StG10H(Nt)CrG10H, the CrG10H(Nt)GrG10H and 







Figure 7. The effect of the N-terminal sequence on geraniol hydroxylation in vivo.   
The N-termini of the G10H library was exchanged for the N-terminus of the functional CrG10H whereas the 
CrG10H N-terminus was exhanged with the StG10H, a variant lacking hydroxylation. Geraniol (grey) and 10HG 








Figure 8. GFP localization of CrG10H and StG10H(Nt)-CrG10H. 
All constructs were expressed under the TDH3p and were seen to localized to the ER. CYP719A21 was included as 




0.24 ± 0.21 mg/L/OD600, respectively. However, the standard deviation observed from 
CrG10H(Nt)RcG10H between triplicate cultures may be resulting in a misrepresentation of 10HG 
accumulation. With the lack of observed 10HG from all but two of the chimeric constructs and 
varying geraniol titers from several strains, the GC-MS spectrums were scrutinized for the 
appearance of new compounds. A unique peak was identified in the CrG10H(Nt)GrG10H spectrum 
putatively identified as neric acid (Appendix Figure A3B, peak 5), which was not present prior to 
the N-terminal exchange (Appendix Figure A3A). Though no increase in 10HG was observed, 
the appearance of neric acid suggests the N-terminus can influence enzyme activity.  
3.4 Optimizing CrG10H activity in S. cerevisiae  
Since optimal CYP:CPR ratios and CYP-CPR fusions have been demonstrated to 
influence substrate turnover115,116,130, both strategies were assessed for their effect on CrG10H 
activity. To this effect, CrG10H copy number was investigated to identify an optimal CYP:CPR 
ratio, wherein multiple copies of CrG10H were iteratively integrated into the single copy 
CrG10H strain. Consistency between each integration was controlled for by ensuring the gene 
expression profiles at each integration site were comparable, as previously identified151, and the 
same promoter-terminator pair was maintained for each integrated CrG10H copy. Furthermore, a 
fusion protein was expressed in the multi-copy CrG10H strain that consisted of a full length 
CrG10H linked to a truncated CrCPR lacking the transmembrane domain.  
As was expected, a higher CrG10H:CrCPR ratio improved substrate turnover (Figure 9A, 
Table 1). A constant increase in 10HG titers can be observed with each additional copy of 
CrG10H, where 3x-CrG10H accumulates a total of 6.22 ± 0.27 mg/L/OD600 (32.09 ± 6.36 mg/L 
after 48 hours). Addition of the CYP-CPR fusion into the 3x-CrG10H strain further improved 
titers to 8.49 ± 0.06 mg/L/OD600, reaching 58.24 ± 3.26 mg/L after 48 hours.  With each 
improvement, it can be noted that geraniol reduction coincides with 10HG accumulation where 
the 3x-CrG10H strain increased the molar conversion of geraniol from 37.6 to 87.0 percent 
(Table 1). A further increase to 92.6 percent molar conversion is seen with the CYP-CPR fusion 
where geraniol titers reach as low as 0.71± 0.23 mg/L/OD600, with assumption that no geraniol is 




Figure 9. Monoterpene production from strains expressing multi-copy CrG10H and CrG10H-CrCPR fusion. 
A) CrG10H was integrated iteratively into strain MD5. The CrG10H-CrCPR fusion was integrated into the 3x-
CrG10H strain.  Geraniol (grey) and 10HG (red) titers and OD600 (•). Error bars represent the standard deviation 
from triplicate cultures. B) Comparison of growth profiles for the multi-copy CrG10H and CrG10H-CrCPR fusion 
production strains. Dotted lines correspond to the standard deviation for quadruplicate cultures. Strain designations 
are as follows: MD5(—), 1x-CrG10H (—), 2x-CrG10H (—), 3x-CrG10H (—) and the CrG10H-CrCPR fusion (—). 
C) Specific growth rate (µmax) for engineered strains from quadruplicate cultures. Asterisk indicates a statistically 
significant (p<0.05) growth rate compared to MD5 strain as determined by Student’s two-sample t-test assuming 
unequal variances with two tailed distribution.  
 
 






With respect to culture growth (ie. OD600) after 48 hours, it appears that the CYP:CPR 
ratio impacts culture cell-density and therefore cell growth (Figure 9A). A decrease in cell 
density can be observed after the addition of a second and third copy of CrG10H compared to 
the 1x-CrG10H strain at 48 hours. Although the integration of CrG10H lowers the growth rate 
compared to MD5 (p<0.05), little change in growth rate is observed following multi-copy 
integration compared to 1x-CrG10H (p>0.05) (Figure 9C). A look into the growth profiles 
demonstrates that each subsequent increase in copy number results in a prolonged lag phase and 
lower growth yields, with a decrease from 3.2 x 107 cells/mL to 2.7 x 107 cells/mL for 1x-
CrG10H and 3x-CrG10H, respectively at 72 hours (Figure 9B). Furthermore, the OD600 of the 
multi-copy strains drop directly proceeding diauxic shift, possibly due to toxic product build-up. 
It appears that the incorporation of the CYP-CPR fusion further alters the growth phenotype, 
where culture densities at 48 hours are comparable to those expressing 1x-CrG10H (Figure 9A). 
The growth profile of the CYP-CPR fusion strain shows similar lag and exponential phases as 
those expressing the 2x-CrG10H but post diauxic shift (around 48 hours) shows a notable change 
in growth. This change in growth may indicate the alleviation of toxic product build-up, which is 
corroborated by the increased molar conversion for this strain resulting in lower geraniol titers 
(Table 1).  Since the results in Figure 9A show a continual increase in 10HG synthesis with no 
observable limit of production following subsequent CrG10H gene additions, the ideal ratio has 
yet to be determined. These results demonstrate the importance of optimizing the proper 
CYP:CPR ratio. Furthermore, although the inclusion of CYP-CPR fusion benefits 10HG 
synthesis in the strain expressing 3x-CrG10H, its individual influence should be assessed to 
determine whether a fourth copy of a G10H alone would have the same effect on 10HG 
synthesis.   
3.5 Combinatorial CPR analysis 
Owing to the high conservation of CYP-CPR interactions, sets of non-cognate enzymes 
from different species or kingdoms can pair effectively and display unique enzyme 
functionality117,119. In other cases, two enzymes may not pair properly. Thus, the lack of activity 
seen for all predicted G10Hs could be caused by a poor interaction with the CrCPR partner. A 
small library of plant CPRs was previously established in our lab with 21 sequences from various 






Figure 10. Analysis of CYP-CPR pairs on monoterpene production. 
A) A bootstrapped maximum likelihood phylogenetic tree of the CPR library rooted by the cytochrome b5 reductase 
(CYB5R) outgroups. B) Monoterpene production. Geraniol (blue) and 10HG (red) production where the results are 
displayed in the above heatmaps. Squares with an ‘X’ represent combinations that were not constructed. The data is 





(PkCPR and VvCPR) for G10Hs in the predicted library. A final list of nine candidate CPRs was 
selected (Figure 10A). The CrCPR was exchanged combinatorially with the candidate CPRs in 
all G10H background strains, and the functionality of each combination was assessed. This 
resulted in a total of 130 different combinations (including the CrCPR combinations); albeit, 
nine combinations were not successfully constructed (Figure 10B, squares with an ‘X’ excluding 
the (-) G10H controls).    
The results from the combinatorial CPR exchange conform with previous reports that 
different CPR partners can influence CYP activity. Varying degrees of geraniol and 10HG titers 
can be observed when the G10Hs are paired with different CPRs (Figure 10B). In both heatmaps, 
the results for the CrCPR strains are displayed in the far-left column with MD5 included as a 
control in which the CrCPR is present but no G10H. The CPRs seem to have a dramatic effect 
on metabolite profiles in comparison to the CrCPR. Most notably are the increases in geraniol 
titers, with several strains improving by over 2-fold, which is especially apparent for JrG10H in 
which geraniol accumulation increased from 5.15 ± 0.74 mg/L/OD600 with the CrCPR to 17.46 ± 
1.06 mg/L/OD600 and 17.79 ± 1.97 mg/L/OD600 with TcCPR and Sr8CPR, respectively (Figure 
10B, Appendix Table A11A and B). Although an increase in geraniol was observed, this did not 
correspond to an increased production of 10HG. Furthermore, several of the new combinations 
resulted in a further decrease in geraniol titers compared to the CrCPR without a corresponding 
increase in 10HG, the most apparent being GriG10H paired with HcCPR or PkCPR. There are a 
few observed instances of 10HG production, GrG10H displays an increase in geraniol 
accumulation that corresponded to the appearance of trace 10HG titers when paired with 
AtG10H (0.57± 0.15 mg/L/OD600) and VvG10H (0.57 ± 0.12 mg/L/OD600) (Appendix Figure 
A11B, Appendix Table A12A and B). 
   Although several of the new CPRs allowed for trace amounts of 10HG from certain 
predicted G10Hs, CrG10H remained the most efficient enzyme at C10 hydroxylation of geraniol 
(Figure 10B, Appendix Table A1 and A2). Additionally, several of the new CPRs increased 
substrate turnover and 10HG accumulation when paired with CrG10H (Figure 10B and 11). 
HcCPR, NsCPR, PkCPR and Sr8CPR increased the molar conversion of geraniol to 10HG from 







Figure 11. Graphical representation of heatmap for monoterpene production of CrG10H with various CPRs. 
Geraniol (grey) and 10HG (red) titers for CrG10H paired with non-cognate CPRs. Error bars represent the standard 








VvCPR were the most notable in terms of 10HG accumulation with titers reaching 4.57 ± 0.46 
mg/L/OD600, 4.73 ± 0.45 mg/L/OD600 and 5.65 ± 0.96 mg/L/OD600, respectively. With the 
identification of several new combinations with improved substrate turnover and product 
accumulation, the same strain optimization rationale (as shown in Figure 9) was used to further 
improve 10HG synthesis. 
3.6 Assessing the 3x-CrG10H strain with non-cognate CPRs 
With the identification of several CPRs that increased activity in the 1x-CrG10H strain 
(Figure 11, Table 2), the same optimization rational was implemented as section 3.4. CPRs were 
selected based on molar conversion, with the assumption that a higher percent molar conversion 
would be advantageous for 10HG biosynthesis – especially once the appropriate copy number is 
determined. With a higher molar conversion, less geraniol would be lost to evaporation and 
further optimization of geraniol synthesis could then improve 10HG titers. It was also 
hypothesized that 10HG would be less toxic to the cells due to the addition of the hydrophilic 
hydroxyl group at the end of the hydrocarbon chain, impairing its ability to insert into 
hydrophobic membranes. To this effect, HcCPR, NsCPR, PkCPR and TcCPR stains were chosen 
as the pairs with the highest observed molar conversion (Table 2). There were difficulties with 
integrating the VvCPR in the 3x-CrG10H background strain and the results for that combination 
are not be present in this thesis. Additionally, Sr1CPR displayed a lower percent molar 
conversion compared to CrCPR and was included to observe its effect at higher copy numbers. 
Integration of the newly identified CPRs into the 3x-CrG10H strain was predicted to 
further increase 10HG titers in proportion to how they fared compared to the CrCPR in the 1x-
CrG10H strain. Using the same design as the combinatorial CPR exchange, the new CPRs were 
integrated into the 3x-CrG10H strain. A time course was carried out for all strains with samples 
taken at 24, 48 and 72 hours with the 1x-CrG10H strain as a control. Figure 12 reports the 
monoterpene profiles after 48 and 72 hours; the 24-hour time point was excluded since the low 
OD600 values resulted in an overestimation of monoterpene titers. The strain harboring NsCPR 
accumulated the most 10HG at both 48 and 72 hours with yields of 6.98 ± 0.52 mg/L/OD600 and 
9.48 ± 0.45 mg/L/OD600, respectively. A similar trend was observed for the strain with CrCPR 
wherein yields increased from 5.81 ± 0.40 mg/L/OD600 (48 hours) to 8.17 ± 0.71 mg/L/OD600 (72 











Figure 12. Monoterpene production from different CPRs in 3x-CrG10H strain. 
Sr1CPR was included as it had a similar percent molar conversion as the CrCPR strain. Geraniol (grey) and 10HG 
(red) titers and OD600 (•) values were measured after 48 and 72 hours, respectively.  Error bars represent the standard 








relatively high titers at 48 hours (5.95 ± 0.19 mg/L/OD600) but 10HG accumulation diminishes 
after 48 hours. The remaining CPRs accumulate around 4 mg/L/OD600 of 10HG at 48 hours and 
display similar or decreased titers at 72 hours (Figure 12). 
Although NsCPR yielded the highest geraniol hydroxylation when normalized to an 
OD600 of 1, the strain showed low optical densities at both time points. Taking this into account, 
the NsCPR strain shows a total 10HG accumulation (non-OD normalized) at 48 and 72 hours of 
14.13 ± 3.33 mg/L and 47.19 ± 3.62 mg/L, respectively, which is lower than the 27.93 ± 4.43 
mg/L and 56.56 ± 4.43 mg/L for the CrCPR strain at both time points (Appendix Figure A4). 
However, considering the observed error of both the NsCPR and CrCPR strains at 72 hours, their 
10HG titers are not statistically different (p>0.05). With respect to total accumulation, the 
HcCPR strain outperforms all strains at 24 and 48 hours accruing 53.09 ± 0.45 mg/L of 10HG. 
Interestingly, only the HcCPR and Sr1CPR strains showed 10HG production at 24 hours with 48 
hours showing the highest 10HG levels followed by a decrease at 72 hours.  
These results may suggest phenotype stability issues with some of the CPRs, namely 
HcCPR and Sr1CPR, possibly due to degradational control where enzyme activity seems to 
decrease after 48 hours. Furthermore, these results suggest a difference in copy-number effects 
between different CPRs, since several of the new CPRs outperformed CrCPR in the 1x-CrG10H 
strain but not in the 3x-CrG10H strain. This is in accordance with previous reports of varying 
optimal ratios between different CYP:CPR pairs118. Moreover, these results identified two 
potential CPRs that may prove to be better partners for the CrG10H. 
3.7 Increasing carbon flux towards 10HG 
3.7.1 Decreasing off-target reactions 
 Throughout the optimization process, the presence of an off-target metabolite became 
more apparent in the GC-MS spectra, coinciding with increased 10HG titers (Figure 13A, peak 
3). This peak was predicted to be isopulegol, according to the NIST08 MS database147, which 
identifies compounds based on reference mass spectra and compound retention time. However, 
due to the lack of an appropriate standard, this cannot yet be confirmed. Chemical synthesis of 
isopulegol usually involves the cyclisation of citronellal using various chemical catalysts152–154. 







Figure 13. Identification of non-productive synthesis of isopulegol. 
A) Total ion abundance for the 3x-CrG10H strain extracted from culture broths. Peak identification using analytic 
standards are as follows: 1. Geraniol; 2. Eugenol (internal standard); 4. 10HG. Peak 3 was predicted by the NIST08 
MS Search as isopulegol. The remaining peaks are standard yeast metabolites.  B) Monoterpene titers in the multi-
CrG10H and CrG10H-CrCPR fusion background strains (left) followed by the subsequent elimination of isopulegol 
content by targeted deletions (right).  Geraniol (grey), 10HG (red) and isopulegol (pink). Due to the lack of an 




isopulegol155,156.  The native yeast old yellow enzymes (Oye2 and Oye3) are NADPH 
oxidoreductases that have previously been observed to reduce geraniol and citral to citronellol 
and citronellal, respectively100,104. These reductions could provide yeast with the appropriate 
substrate for isopulegol synthesis.  This peak appeared after the integration of CrG10H and the 
presence of multiple CrG10H copies further increased isopulegol peak area (Figure 13B). The 
most notable increase coincided with the addition of the second CrG10H copy, increasing peak 
area from 6,628.59 ± 3,061.08 ion abundance•min/OD600 to 72,037.61 ± 8,219.94 ion 
abundance•min/OD600. Following this identification, the G10H variant library was analyzed for 
isopulegol content, however the results indicate that this product is relatively unique to CrG10H 
with only trance abundances detected from GrG10H, HrG10H and RcG10H (Appendix Figure 
A5A). Furthermore, the exchange of the CrG10H N-terminus for the StG10H counterpart 
reduced accumulation (Appendix Figure A5B).  Isopulegol content also varied depending on the 
paired CPR. In the 1x-CrG10H strain, Sr1CPR accumulated more isopulegol compared to the 
other backgrounds (Appendix Figure A6A), however, in the 3x-CrG10H strain, HcCPR 
displayed the highest isopulegol content (Appendix Figure A6B).  
To explore the possibility of Oye2 and Oye3’s role in the formation of isopulegol, both 
homologs were deleted iteratively from the 1x-CrG10H strain. Since Oye2 can reduce geraniol 
and citral to citronellol and citronellal, respectively, Oye3 was deleted first to determine its effect 
on isopulegol production. Deletion of Oye3 was observed to increase both 10HG and isopulegol 
from 1.99 ± 0.31 mg/L/OD600 to 3.62 ± 0.13 mg/L/OD600 and 6,628.58 ± 3,061 ion 
abundance•min/OD600 to 26,955.54 ± 523.09 ion abundance•min/OD600, respectively (Figure 
13B). Further deletion of Oye2 eliminated isopulegol production resulting in 6.47 ± 0.74 
mg/L/OD600 and 25.33 ± 1.81 mg/L/OD600 of 10HG in the 1x-CrG10H and 3x-CrG10H 
backgrounds, a 3.3- and 4-fold increase, respectively. Corresponding to a total 10HG 
accumulation (non OD600 normalized) of 144.04 ± 5.10 mg/L in the 3x-CrG10H strain 
background.  
The effect of deleting these reductases is not only apparent in the monoterpene profiles 
but an altered growth phenotype is observed upon Oye3 deletion compared to the 1x-CrG10H 











Figure 14. Growth profiles for deletion of Oye3 and Oye2 from engineered S. cerevisiae. 
A) Comparison of growth profiles for CrG10H (—), CrG10H Δoye3 (—) and CrG10H Δoye3 Δoye2 (—) strains. 
The dotted lines correspond to the standard deviation quadruplicate cultures. B) Specific growth rate (µmax) for 
engineered strains from quadruplicate cultures. Asterisk indicates statistically significant (p<0.05) growth rates 
compared to the strain expressing CrG10H as determined by Student’s two-sample t-test assuming unequal 








strain, where a slight increase in growth rate (p<0.05) is observed followed by a notable change 
post-diauxic shift as growth seem to increase much more rapidly in comparison to the 1x-
CrG10H strain (Figure 14B). The growth phenotype remains consistent following Oye2 deletion, 
possibly indicating Oye3 is responsible for the altered growth. 
3.7.2 Overall increase in carbon flux towards 10-hydroxygeraniol 
 The overarching goal in optimizing G10H activity was to increase total carbon allocation 
towards 10HG biosynthesis by improving inefficient reactions and minimizing off-target 
products. These initial attempts in optimizing CrG10H activity were successful in channeling 
more carbon towards 10HG, achieving a modest total increase (non-OD600 normalized) from 
34.84 ± 3.64 mg/L (1x-CrG10H) to 37.47 ± 8.35 mg/L and 63.07 ± 4.66 mg/L for the 3x-
CrG10H and CYP-CPR fusion strains respectively (Figure 15). Moreover, optimization of the 
1x-CrG10H strain by mitigating off-target reactions via OYE deletions, further improved the 
total carbon directed towards 10HG. Successive deletions increased 10HG accumulation, and 
therefore total carbon, with total carbon content yielding 46.82 ± 4.27 mg/L (Δoye3) and 63.86 ± 
2.36 mg/L (Δoye2Δoye3), a 1.3- and 1.8- fold improvement, respectively. Deletion of these 
reductases from the final 3x-CrG10H strain achieved a total carbon content at 160.72 ± 7.56 
mg/L. Further deletion of these reductases from the CYP-CPR fusion strain has the potential to 
significantly increase 10HG titers.  
 
4. DISCUSSION 
 Optimizing 10HG production in S. cerevisiae lays the foundation for a more sustainable 
and economical means to produce nepetalactone and MIAs. With the elucidation of the 
strictosidine biosynthetic pathway and the identification of several limiting steps, engineering of 
a high-producing strain is possible. Optimization of the initial heterologous bottleneck in the 
nepetalactol/strictosidine pathway in S. cerevisiae is dependent on several factors: redirecting 
carbon from FPP synthesis towards GPP via Erg20 mutation, increasing carbon flux through the 
MVA pathway bottleneck, optimizing heterologous expression of G10H and reducing off-target 
reactions. By addressing each area, 10HG production has been optimized for future nepetalactol 









Figure 15. Total monoterpene accumulation for optimized CrG10H strains. 
Monoterpene titers in the multi-CrG10H and CrG10H-CrCPR fusion background strains (left) followed by the 
subsequent elimination of isopulegol content by targeted deletions (right). Geraniol (grey) and 10HG (red) and 









4.1 Redirecting carbon for GPP production 
The identification of several Erg20 mutations allowing the release of GPP enables the 
first essential step towards monoterpene production in S. cerevisiae – available precursor supply. 
The Erg20K197E mutation59 was previously introduced into S. cerevisiae CEN.PK, in place of the 
native Erg20, by Campbell et al.58. The observable growth defect of this mutant strain can be 
explained by the essential nature of this enzyme (Figure 5B). With roles in sterol biosynthesis, 
contributing to membrane structure and cell-wall synthesis, as well as protein prenylation and 
ubiquinone synthesis, redirecting carbon away from this pathway negatively impacted cell 
growth157. In addition, cell culture growth was further hampered by the toxic nature of geraniol 
on S. cerevisiae. Geraniol is an essential plant oil with antifungal properties, wherein S. 
cerevisiae displays a minimum inhibitory concentration between 200-400 mg/L with 150 mg/L 
causing a slight inhibition106,158. With these concentrations in mind, no growth defects should be 
observed for MD5 since geraniol titers hovered around 43.45 ± 1.84 mg/L after 48 hours. 
However, the volatility of geraniol may result in underestimating actual yields, where a study 
reported an 87.8% loss of radiolabeled geraniol (99% purity) after 21 hours159. This volatility is 
corroborated by the extensive use of biphasic systems aimed at trapping geraniol, as well as other 
terpenoids, for metabolite analysis. These biphasic systems generally use the alkane 
hydrocarbon, dodecane, which is well suited for capturing terpenoids and is biocompatible 
with S. cerevisiae106,109,160–162. The observance of toxic effects pre- and post- diauxic shift for 
strains MD4 and MD5 suggest geraniol titers may hover in the 150 mg/L range, however a 
dodecane biphasic growth system should be optimized to identify exact titers. Regardless of 
toxicity, initial strain optimizations increased in vivo geraniol levels. 
4.2 Assessing the activity of the G10H variant library 
We hypothesized that geraniol toxicity could be alleviated by hydroxylating geraniol to 
10HG by G10H. Since the mechanism of geraniol toxicity involves the permeabilization of cell 
membranes158,163, addition of the hydroxyl group may decrease membrane disruption by 
preventing insertion of the hydrocarbon tail into lipid bilayers. Unfortunately, no 10-
hydroxygeraniol was directly observed for the G10H variants aside from CrG10H (Figure 6B). 
The decrease in geraniol titers for several of the variants suggests the occurrence of non-C10 
hydroxylation reactions, where geraniol may be a substrate for secondary reactions involving 
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oxidations, rearrangements or reductions - activities not uncommon to CYPs164. Alternatively, 
these variants may catalyze sequential reactions initiated by C10 hydroxylation of geraniol, 
resulting in final products undetectable by GC-MS. A multi-functional CYP was documented by 
Liu et al. that catalyzed several consecutive reactions, beginning with C3 hydroxylation of the 
sesquiterpene substrate, followed by water elimination, cyclization and regioselective 
deprotonation165. Bifunctional CYPs have been identified in monoterpene biosynthesis that 
catalyzes sequential stereoselective hydroxylation and carbon–carbon bond cleavage166. 
Conversely, G10H variants that increase geraniol titers in comparison to MD5 may suggest 
geraniol synthase activity, utilizing GPP as a substrate. This is supported by the previous 
characterization of a CYP monooxygenase with a secondary terpene synthase active site able to 
synthesize farnesene isomers from FPP167. Analysis of the G10H variant library using the 
ExPASy ScanProsite tool168 indicated that a characteristic, highly conserved terpene synthase 
Mg2+ binding motif (DDXX(D/E))169 was present in the HaG10H and HrG10H variants, possibly 
explaining the increase in geraniol accumulation in the HaG10H background. Since the HrG10H 
strain did not accumulate more geraniol compared to MD5, the lowered geraniol levels indicate 
the variant may have geraniol-based synthase activity.  
After identifying the putative terpene synthase domains, the G10H candidates were 
systematically searched for conserved domains using NCBI delta-blast133 which uses domain 
conservation to identify remote protein homologs. All but two variants (HrG10H and RcG10H) 
were predicted to contain an allene oxide synthase domain (averaging E scores of 1e-7), a CYP 
that catalyses the unusual dehydration of lipoxygenase products to unstable allene epoxides170. It 
is unclear whether this domain can influence geraniol accumulation. Although these variants 
may not possess C10 geraniol hydroxylation activity and/or may possess other activities, there is 
the possibility that their heterologous expression is influencing their activity.  
The lack of geraniol hydroxylation activity may partially be explained by the nature of 
the ER membrane in S. cerevisiae. While the catalytic domain of a CYP is largely cytosolic, 
hydrophobic helices embedded the protein in the ER membrane where substrate channels can 
open both to the cytosol and the membrane adjacent to where these helices interact171. Several 
researchers have characterized the influence of CYP and membrane lipid interactions on enzyme 
catalytic function and efficiency172–176. For instance, the phospholipid composition of the 
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membrane interacting with the catalytic domain can influence substrate binding and enzymatic 
activity of CYPs177. Murtazina et al. observed variations in CYP substrate specificity and 
enzymatic activity depending on the phospholipid composition of the in vitro lipid expression 
vesicle177. Although the phospholipid content of the ER in S. cerevisiae178 falls within the range 
of plant ER phospholipid content, variations in plants are observed across tissues and species179. 
Furthermore, CYP activity can be affected by the specific N-terminal anchor sequence; 
influencing CYP-membrane interactions and thus the interaction with membrane 
phospholipids176.  
4.3 Assessing differential activity from chimeric G10H variants 
The CYP N-terminal transmembrane domain is important for protein orientation, 
stabilizing protein interactions with membrane phospholipids, thereby affecting the catalytic 
activity of heterologously expressed proteins124,176,180. To this effect, the N-termini of the CYP 
variants were exchanged for that of CrG10H, an enzyme with 10HG activity in S. cerevisiae. 
Unfortunately, the chimeras displayed no new identified hydroxylation activities (Figure 7), 
although the CrG10H(Nt)GrG10H strain did start producing a compound predicted to be neric acid 
(Appendix Figure A3). Neric acid is derived from the monoterpene nerol following the 
dephosphorylation of neryl pyrosphsphate, the cis-isomer of GPP181. This peak was not detected 
in the GrG10H chromatograms prior to the N-terminal exchange, suggesting an altered 
arrangement imparted nerol synthase activity.  However, since GrG10H does not have the 
characteristic terpene synthase domains, it may be acting as an isomerase using geraniol or 
geranial as the substrate. This altered activity may explain the differences in geraniol yields for 
several of the variants between their respective wild type and chimeric backgrounds. Changing 
the N-terminus may alter how the CYP interacts with the membrane, modifying active site 
accessibility or substrate specificity. This may further explain why the StG10H(Nt)CrG10H chimera 
retains metabolite profiles from both StG10H and CrG10H (Figure 6B and 7). In addition, 
StG10H(Nt)CrG10H protein levels appear to be lower than CrG10H, suggesting the N-terminus can 
modify expression or protein regulation (Figure 8). However, both the wild type and the chimera 
accumulate similar levels of 10HG (Figure 7), suggesting the chimera is more efficient, possibly 
due to increased substrate access. Not only does the transmembrane domain influence the 
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interaction of the protein with phospholipids, but the N-terminus may regulate the efficiency of 
CYP-CPR interactions and therefore may influence their catalytic efficiency176,180,182,183. 
4.4 CPR influence on CYP activity 
Recent studies have postulated that the transmembrane domain composition and the 
membrane itself may have a role in CYP-CPR coupling efficiency, referring to the amount of 
transferred electrons committed to the monooxygenase activity versus “uncoupled” (or 
unproductive) pathways.  The orientation of the CYP and the CPR, dictated by their respective 
N-termini, can influence unproductive reactions, namely, release of superoxide from the ferrous 
dioxygen, release of hydrogen peroxide, and the 4e − reduction of heme to produce water184. The 
varying degrees of monoterpene profiles between different CYP-CPR pairs in Figure 10B may 
be explained by coupling efficiencies. Since no observable trend was identified within a single 
CPR or G10H lineage, the results suggest that coupling efficiencies are depended on the specific 
CYP-CPR pair. In the case of the strain expressing 1x-CrG10H, the non-cognate CPRs increased 
coupling efficiencies thereby increasing substrate turnover resulting in higher 10HG titers. A 
further increase in coupling may be attainted with the upregulation of Ice2, a type III membrane 
protein in S. cerevisiae involved in maintaining ER morphology185,186. Overexpression has been 
shown to stabilize CPR levels and activity over extended periods of bioconversion, which may 
benefit prolonged production of 10HG. Furthermore, it would be interesting to assess the effect 
of the native S. cerevisiae CPRs on G10H activity. Nonetheless, with the identification of several 
CPRs shown to improve efficiency of the CYP catalyzed conversion, further optimization 
strategies allowed for increased 10HG production. 
The introduction of the more efficient, non-cognate CPRs into the 3x-CrG10H strain 
resulted in unexpected differences in molar conversion compared to the 1x-CrG10H background 
(Figure 11 and 12). It was expected that 10HG production would increase proportionally in 
accordance with the CPRs’ influence in the 1x-CrG10H strain. However, introduction of these 
CPRs into the 3x-CrG10H strain resulted in a close competition between CrCPR, HcCPR and 
NsCPR, suggesting a more efficient coupling between CrG10H and CrCPR at a 3:1 ratio. This 
relates back different optimal CYP:CPR ratios for different enzyme partners, wherein HcCPR or 
NsCPR may require a higher CYP:CPR ratio for optimal coupling. In this regard, delta-CRISPR 
could be used as a high-throughput means to assess optimal ratios, wherein multiple G10Hs 
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could be integrated into the Ty retrotransposon delta sites in the yeast genome187–189. However, 
an important aspect remains to be addressed for the 3x-CrG10H strain harboring NsCPR, the low 
OD600 for this strain could influence its position as a better alternative to CrCPR.  
This observed growth defect may be explained by the N-end rule, relating the in vivo 
half-life of a protein to the N-terminal residue directly after the initial Met residue. A hierarchical 
structure has been identified characterizing the destabilising effect of the N-terminal residue and 
determining the nature of the N-degron (degradation signals targeted by the N-end rule 
pathway)190–192. For the CPRs tested in the strain expressing 3x-CrG10H, NsCPR had an N-
terminal residue denoting a protein half-life of >20h, with the remaining CPRs falling below 30 
minutes190. A short in vivo lifetime could imply a less stringent control over the relative rates of 
synthesis, since proteins produced in excess would not accumulate to a significant level193. Since 
NsCPR has a high in vivo half-life, degradation rates are slower compared to the other CPRs and 
may result in ER flooding, causing cell growth defects194. Alternatively, NsCPR may donate 
electrons at a higher turnover rate but also have a higher degree of uncoupling, potentially 
resulting in increased H2O2 production and cell toxicity. It would be interesting to analyze the 
effect of different CPR N-end residues on cell growth and 10HG production. Even with the 
growth impairment, NsCPR remains one of the best candidates for optimal 10HG production 
along with HcCPR and CrCPR. 
4.5 Identification and reduction of off-target metabolism 
The last requirement for optimal 10HG production in S. cerevisiae was to mitigate off-
target products responsible for sequestering carbon away from 10HG biosynthesis. The putative 
identification of isopulegol suggested a carbon sink that could limit 10HG accumulation. A 
logical synthesis scheme can be derived involving native yeast enzymes combined with a 
potential heterologous cyclase, where geraniol or 10HG undergo a sequential oxidation/reduction 
combination to produce citronellal, followed by cyclisation to isopulegol (Figure 16). As 
explained earlier Oye2 has been shown to reduce geraniol and citral to citronellol and citronellal, 
respectively; citronellal has been used extensively as the starting material for direct chemical 
synthesis of isopulegol152–154,195,196. Furthermore, several S. cerevisiae alcohol dehydrogenases 
are capable of oxidizing a primary alcohol to an aldehyde, namely Adh6 and Adh7, which have 
displayed activity on 10HG, converting it to 10-hydroxgeranial102. A recent study developed an 
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enzyme cascade to selectively convert citral to isopulegol by combining a bacterial ene-reductase 
OYE homolog and a squalene hopene cyclase197. To this effect, three possible biosynthetic 
routes can be proposed, two of which begin with geraniol and one branching from 10HG (Figure 
16). For route 1 geraniol is reduced to citronellol, followed by oxidation to citronellal. Route 2 
involves geraniol oxidation to citral, followed by reduction to citronellal and similarly route 3 
branches from 10HG and involves an oxidation to 10-hydroxygeranial and reduction to 10-
hydroycitronellal.  In the case of route 3, 10-hydroxycitronellal is used as the direct substrate for 
isopulegol synthesis or undergoes a dehydration reaction to an alkene followed by reduction to 
citronellal.  
The final cyclisation of citronellal to isopulegol may be directly catalyzed by CrG10H 
since this activity was not observed prior to CrG10H integration and isopulegol abundances 
increase with multiple CrG10H copies. Moreover, isopulegol accumulation is limited to the 
strains expressing CrG10H, apart from two exceptions in which small accumulations can be 
observed (Appendix Figure A5). Additionally, N-terminal modification of CrG10H influences 
isopulegol accumulation. With respect to terpene cyclase, CrG10H does not have the 
characteristic aspartate-rich motifs conserved among this class of enzyme, however, Itoh et al. 
characterized a novel set of terpene cylases similarly lacking these conserved domains198. 
Furthermore, Lichman et al. characterized a set of non-oxidoreductive cyclases from N. mussinii, 
NEPS, that are involved in the cyclisation of 10-oxogeranial to nepetalactol and similarly lack 
the conserved terpene cyclase domains89. Therefore, CrG10H may be responsible for the 
cyclisation, though further analyses will be required for conformation.  
4.6 Potential effect of OYE deletions on cell growth 
The OYE homologs have featured prominently in the non-productive reduction of 
monoterpene intermediates100–104. In this study, Oye2 was directly involved in producing the off-
target metabolite, predicted to be isopulegol, as its removal abolished accumulation. In contrast, 
Oye3 deletion increased 10HG and isopulegol levels, suggesting Oye3 diverts carbon by 
converting a pathway intermediate to an unknown product. The Δoye3 strain displayed 
pronounced diauxic shifts (Figure 14A), similar to the CYP-CPR fusion, possibly implying Oye3 













Figure 16. In vivo synthesis scheme of isopulegol in S. cerevisiae. 
Based on the observed influence of the oye2 deletion on isopulegol accumulation, three hypothetical in vivo 
biosynthetic routes can be proposed. These routes all proceed via differential combinations of the same native yeast 
enzymes, Oye2 and an Adh. Solid black lines indicate a prior observance of this exact or related activity. Hashed 
grey lines indicate unknown but possible steps and hashed black lines indicate the hypothesized step responsible for 




Collectively, previous studies suggest a model for geraniol-based growth defects and 
rescue by Δoye3. Geraniol production likely causes loss of the diauxic shift by inhibiting yeast 
cells through cell membrane permeabilization, leading to K+ efflux and membrane 
depolarization158,163. K+ efflux drives ROS-induced programmed cell death (PCD) by the de-
repression of PCD-specific hydrolytic enzymes (proteases and endonucleases), normally 
inhibited by high K+ concentrations199,200. This decrease in osmolarity stimulates oxidative 
metabolism, leading to enhanced intracellular ROS production, which the cell integrity pathway 
addresses by redirecting protein kinase C to areas of compromised membrane integrity for ROS 
management201. Unfortunately for the cell, geraniol can inhibit protein kinase C163, hampering 
the pathway involved in mitigating the ROS-induced PCD initiated by geraniol. Furthermore, 
aceto-acetyl CoA and HMG-CoA are subject to glucose repression so the majority of geraniol 
accumulation occurs post diauxic shift, during growth on ethanol202. This accumulation is in 
tandem with increased ROS formation from mitochondrial respiration, ultimately increasing the 
effect of osmotic stress and premature PCD, causing cell growth to flat-line post diauxic shift. 
 In response to ROS, the OYE homologs heterodimerize and influence H2O2-induced 
PCD203,204. Individually they have opposing roles whereby Oye2 alone is a potent antioxidant, 
mitigating ROS formation and suppressing PCD, however, Oye3 seems to be directly involved in 
H2O2-induced PCD, antagonizing the protective action of Oye2
203,205. The activity of Oye3 is 
dependent on the presence of Oye2. Thus, deletion of Oye3 prevents Oye2 sequestration and 
increases cell survival in the presence of H2O2
203. Taking this into account, removal of Oye3 may 
lessen the oxidative stress response that is responsible for initiating ROS mediated PCD, 
therefore increasing cell survival post diauxic shift, resulting in increased OD600 values during 
respiration. However, to validate this hypothesis, the OYE deletions should be performed 
individually and in tandem in the geraniol overexpressing MD5 to asses changes in growth 
phenotype.  
Interestingly, this increase in cell growth post diauxic shift was mimicked by the CYP-
CPR fusion strain which exhibited a similar growth phenotype to the Δoye3 strain (Figure 9B and 
14A). While the cause in unclear, it may be worth testing a strain with multiple CYP-CPR 
fusions to observe the effect on growth. It would also be interesting to observe the individual 
effects of a fourth and second copy of a CrG10H and a CrCPR respectively, as well as both 
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together (un-fused) into the 3x-CrG10H strain. This would aid in elucidating the reason for these 
altered growth phenotypes, as well as the CYP-CPR fusions’ influence on 10HG synthesis.  
Collectively, this study found multiple modifications that boost 10HG biosynthesis and 
made key observations that will inform future improvements for synthesis. Having identified 
optimal CPRs, appropriate CYP:CPR ratios can now be determined to enhance coupling for 
monooxygenase activity. Moreover, incorporation of known mutations that stabilize CYP-CPR 
interactions, improve enzyme turnover and promote cell growth should now be pursued. Finally, 
introduction of the CYP-CPR fusion and the Δoye2Δoye3 into the optimal strain backgrounds 
could further increase 10HG biosynthesis. 
 
5. CONCLUSION 
 This study revealed multiple ways to improve the yield of heterologously produced 10HG 
in S. cerevisiae, ultimately for nepetalactol and strictosidine biosynthesis. The overexpression of 
the two key MVA genes paired with the Erg20K197E mutant was successful in modulating the 
carbon flow for geraniol production. Though the G10H variants did not directly display novel 
C10 geraniol hydroxylation abilities, numerous CPRs beneficially influenced CrG10H 
monooxygenase activity. Finally, the mitigation of off-target metabolite synthesis increased the 
amount of carbon allocated to 10HG biosynthesis. Together, the optimization strategies of this 
study add to the growing cohort of strictosidine pathway improvements and will accelerate 
efforts to replace the current inefficient and uneconomical production strategies of commercially 
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K197E-loxP-kanMX ERG20 CEN.PK113 [61] 
MD2 PPGK-tHMGR-TTDH2-PTEF1-IDI-TCYC1 USERXII-2 MD1 This study 
MD3 PTEF2-ObGES-TTDH2 FgF20 MD2 This study 
MD4 PTEF2-t63ObGES-TTDH2 FgF20 MD2 This study 
MD5 PPYK1-AgGPPS-TENO2-PPDC1-CrCPR-TADH2 USERXII-3 MD4 This study 
G10H 
variants 
MD6 PTEF1-CrG10H-TADH1 USERXII-5 MD5 This study 
MD7 PTEF1-BsG10H- TADH1 USERXII-5 MD5 This study 
MD8 PTEF1-EgG10H- TADH1 USERXII-5 MD5 This study 
MD9 PTEF1-GrG10H- TADH1 USERXII-5 MD5 This study 
MD10 PTEF1-GriG10H- TADH1 USERXII-5 MD5 This study 
MD11 PTEF1-HaG10H- TADH1 USERXII-5 MD5 This study 
MD12 PTEF1-HrG10H- TADH1 USERXII-5 MD5 This study 
MD13 PTEF1-InG10H- TADH1 USERXII-5 MD5 This study 
MD14 PTEF1-JrG10H- TADH1 USERXII-5 MD5 This study 
MD15 PTEF1-PkG10H- TADH1 USERXII-5 MD5 This study 
MD16 PTEF1-PpG10H- TADH1 USERXII-5 MD5 This study 
MD17 PTEF1-RcG10H- TADH1 USERXII-5 MD5 This study 
MD18 PTEF1-SaG10H- TADH1 USERXII-5 MD5 This study 
MD19 PTEF1-StG10H- TADH1 USERXII-5 MD5 This study 
MD20 PTEF1-VvG10H- TADH1 USERXII-5 MD5 This study 
N-terminal 
exchange 
MD21 PTEF1-StG10H(Nt)-CrG10H- TADH1 USERXII-5 MD5 This study 
MD22 PTEF1-CrG10H(Nt)-BsG10H- TADH1 USERXII-5 MD5 This study 
MD23 PTEF1-CrG10H(Nt)-GrG10H- TADH1 USERXII-5 MD5 This study 
MD24 PTEF1-CrG10H(Nt)-GriG10H- TADH1 USERXII-5 MD5 This study 
MD25 PTEF1-CrG10H(Nt)-HaG10H- TADH1 USERXII-5 MD5 This study 
MD26 PTEF1-CrG10H(Nt)-HrG10H- TADH1 USERXII-5 MD5 This study 
MD27 PTEF1-CrG10H(Nt)-JrG10H- TADH1 USERXII-5 MD5 This study 
MD28 PTEF1-CrG10H(Nt)-PkG10H- TADH1 USERXII-5 MD5 This study 
MD29 PTEF1-CrG10H(Nt)-RcG10H- TADH1 USERXII-5 MD5 This study 
MD30 PTEF1-CrG10H(Nt)-SaG10H- TADH1 USERXII-5 MD5 This study 
MD31 PTEF1-CrG10H(Nt)-StG10H- TADH1 USERXII-5 MD5 This study 
MD32 PTEF1-CrG10H(Nt)-VvG10H- TADH1 USERXII-5 MD5 This study 
GFP strains 
MD33 PTDH3-CrG10H-ENVY-TTDH1 FgF16 BY4741 This study 
MD34 PTDH3- StG10H(Nt)-CrG10H- ENVY-TTDH1 FgF16 BY4741 This study 
MD35 PTDH3-CYP719A21- ENVY-TTDH1 FgF16 BY4741 This study 
CrG10H 
optimization 
MD36 PTEF1-CrG10H- TADH1 Fgf16 MD5 This study 
MD37 PTEF1-CrG10H- TADH1 Fgf24 MD36 This study 
MD38 PPGK-CrG10H-CrCPR- TADH1 106a MD37 This study 
CrG10H - 
CPR swap 
MD39 AtCPR CrCPR MD6 This study 
MD40 HcCPR CrCPR MD6 This study 
MD41 NdCPR CrCPR MD6 This study 
MD42 NsCPR CrCPR MD6 This study 
MD43 PkCPR CrCPR MD6 This study 
MD44 Sr1CPR CrCPR MD6 This study 
MD45 Sr8CPR CrCPR MD6 This study 
MD46 TcCPR CrCPR MD6 This study 
MD47 VvCPR CrCPR MD6 This study 
BsG10H - 
CPR swap 
MD48 HcCPR CrCPR MD7 This study 
MD49 NdCPR CrCPR MD7 This study 
MD50 NsCPR CrCPR MD7 This study 
MD51 PkCPR CrCPR MD7 This study 
MD52 Sr1CPR CrCPR MD7 This study 
MD53 Sr8CPR CrCPR MD7 This study 
MD54 TcCPR CrCPR MD7 This study 
MD55 VvCPR CrCPR MD7 This study 
GrG10H - 
CPR swap 
MD56 AtCPR CrCPR MD9 This study 
MD57 HcCPR CrCPR MD9 This study 
MD58 NdCPR CrCPR MD9 This study 
MD59 NsCPR CrCPR MD9 This study 
MD60 Sr1CPR CrCPR MD9 This study 
MD61 Sr8CPR CrCPR MD9 This study 
MD62 TcCPR CrCPR MD9 This study 
MD63 VvCPR CrCPR MD9 This study 
GriG10H - 
CPR swap 
MD64 HcCPR CrCPR MD10 This study 
MD65 NdCPR CrCPR MD10 This study 
MD66 NsCPR CrCPR MD10 This study 
MD67 PkCPR CrCPR MD10 This study 
MD68 Sr8CPR CrCPR MD10 This study 
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MD69 VvCPR CrCPR MD10 This study 
HaG10H - 
CPR swap 
MD70 AtCPR CrCPR MD11 This study 
MD71 HcCPR CrCPR MD11 This study 
MD72 NdCPR CrCPR MD11 This study 
MD73 NsCPR CrCPR MD11 This study 
MD74 PkCPR CrCPR MD11 This study 
MD75 Sr1CPR CrCPR MD11 This study 
MD76 Sr8CPR CrCPR MD11 This study 
MD77 TcCPR CrCPR MD11 This study 
MD78 VvCPR CrCPR MD11 This study 
HrG10H-
CPR swap 
MD79 AtCPR CrCPR MD12 This study 
MD80 HcCPR CrCPR MD12 This study 
MD81 NdCPR CrCPR MD12 This study 
MD82 NsCPR CrCPR MD12 This study 
MD83 PkCPR CrCPR MD12 This study 
MD84 Sr1CPR CrCPR MD12 This study 
MD85 Sr8CPR CrCPR MD12 This study 
MD86 TcCPR CrCPR MD12 This study 
MD87 VvCPR CrCPR MD12 This study 
JrG10H-
CPR swap 
MD88 AtCPR CrCPR MD14 This study 
MD89 HcCPR CrCPR MD14 This study 
MD90 NdCPR CrCPR MD14 This study 
MD91 NsCPR CrCPR MD14 This study 
MD92 PkCPR CrCPR MD14 This study 
MD93 Sr1CPR CrCPR MD14 This study 
MD94 Sr8CPR CrCPR MD14 This study 
MD95 TcCPR CrCPR MD14 This study 
MD96 VvCPR CrCPR MD14 This study 
PkG10H-
CPR swap 
MD97 AtCPR CrCPR MD15 This study 
MD98 HcCPR CrCPR MD15 This study 
MD99 NdCPR CrCPR MD15 This study 
MD100 NsCPR CrCPR MD15 This study 
MD101 PkCPR CrCPR MD15 This study 
MD102 Sr1CPR CrCPR MD15 This study 
MD103 Sr8CPR CrCPR MD15 This study 
MD104 TcCPR CrCPR MD15 This study 
MD105 VvCPR CrCPR MD15 This study 
PpG10H-
CPR swap 
MD106 AtCPR CrCPR MD16 This study 
MD107 HcCPR CrCPR MD16 This study 
MD108 NdCPR CrCPR MD16 This study 
MD109 NsCPR CrCPR MD16 This study 
MD110 PkCPR CrCPR MD16 This study 
MD111 Sr1CPR CrCPR MD16 This study 
MD112 Sr8CPR CrCPR MD16 This study 
MD113 TcCPR CrCPR MD16 This study 
MD114 VvCPR CrCPR MD16 This study 
RcG10H-
CPR swap 
MD115 AtCPR CrCPR MD17 This study 
MD116 HcCPR CrCPR MD17 This study 
MD117 NdCPR CrCPR MD17 This study 
MD118 NsCPR CrCPR MD17 This study 
MD119 PkCPR CrCPR MD17 This study 
MD120 Sr1CPR CrCPR MD17 This study 
MD121 Sr8CPR CrCPR MD17 This study 
MD122 TcCPR CrCPR MD17 This study 
MD123 VvCPR CrCPR MD17 This study 
SaG10H-
CPR swap 
MD124 AtCPR CrCPR MD18 This study 
MD125 HcCPR CrCPR MD18 This study 
MD126 NdCPR CrCPR MD18 This study 
MD127 NsCPR CrCPR MD18 This study 
MD128 PkCPR CrCPR MD18 This study 
MD129 Sr1CPR CrCPR MD18 This study 
MD130 Sr8CPR CrCPR MD18 This study 
MD131 TcCPR CrCPR MD18 This study 
MD132 VvCPR CrCPR MD18 This study 
StG10H-
CPR swap 
MD133 AtCPR CrCPR MD19 This study 
MD134 HcCPR CrCPR MD19 This study 
MD135 NdCPR CrCPR MD19 This study 
MD136 NsCPR CrCPR MD19 This study 
MD137 PkCPR CrCPR MD19 This study 
MD138 Sr1CPR CrCPR MD19 This study 
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MD139 TcCPR CrCPR MD19 This study 
MD140 VvCPR CrCPR MD19 This study 
VvG10H-
CPR swap 
MD141 AtCPR CrCPR MD20 This study 
MD142 NdCPR CrCPR MD20 This study 
MD143 NsCPR CrCPR MD20 This study 
MD144 Sr1CPR CrCPR MD20 This study 
MD145 TcCPR CrCPR MD20 This study 
MD146 VvCPR CrCPR MD20 This study 
3x-CrG10H 
- CPR swap 
MD147 HcCPR CrCPR MD37 This study 
MD148 NsCPR CrCPR MD37 This study 
MD149 PkCPR CrCPR MD37 This study 
MD150 Sr1CPR CrCPR MD37 This study 
MD151 TcCPR CrCPR MD37 This study 
OYE 
deletions 
MD152 LP2.T10 OYE3 MD6 This study 
MD153 LP2.T10 OYE2 MD152 This study 
MD154 LP2.T10 OYE2/OYE3 MD37 This study 
 
 
Table A2. Plasmids used throughout this thesis. 




Modified from Ryan et al. (2014) 
Addgene #60847 
pCas-Tyr-gRNA1 gRNA1 is targeted to USERXII_2 This study 
pCas-Tyr-gRNA2 gRNA2 is targeted to FgF20 This study 
pCas-Tyr-gRNA3 gRNA3 is targeted to USERXII_5 This study 
pCas-Tyr-gRNA4 gRNA4 is targeted to FgF16 This study 
pCas-Tyr-gRNA5 gRNA5 is targeted to FgF18 This study 
pCas-Tyr-gRNA6 gRNA6 is targeted to 106a This study 
pCas-Tyr-gRNA7 gRNA7 is targeted to CrCPR This study 
pCas-Tyr-gRNA8 gRNA8 is targeted to OYE3 This study 
pCas-Tyr-gRNA9 gRNA9 is targeted to OYE2 This study 
pYES_pGerOH 
2μori, URA3, PPYK1-AgGPPS2-TENO2 -PPDC1-CrCPR-TADH2-PTEF2-ObGES-TTDH2 -PFBA1-
CrG10H-TPGI1 
Campbell et al. (2016) 
Thermofisher 
pJet_BsG10H BsG10H This study 
pJet_HaG10H HaG10H This study 
pJet_HrG10H HrG10H This study 
pJet_InG10H InG10H This study 
pJet_JrG10H JrG10H This study 
pJet_PkG10H PkG10H This study 
pJet_PpG10H PpG10H This study 
pJet_RcG10H RcG10H This study 
pJet_SaG10H SaG10H This study 
pJet_StG10H StG10H This study 
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OYE2_F with 3' homology to HDV 
pCas universal 
gRNA primers 
LB33 CACCTATATCTGCGTGTTGC pCas_HDV_F 
- 
LB34 GTCAAGACTGTCAAGGAGG pCas-scaffold_R 
 
 












































Truncation of ObGES at position 63_F with 5' 





















CrCPR cassette_R with 3' homology to LV5 
 
 







































































































































































































































































































































































VvCPR_R with 3' homology to ADH2t 
 
 






































tCrCPR_F with GST linker and 3' homology to 
CrG10H 
 

















DOWN region_F with 5' homology to LV5 
MD8 CCAACGCATTTACAAACCACG DOWN region_R 
USERXII-5 








DOWN region_F with 5' homology to LV5 





UP region_R with 3' homology to LV3 
MD250 TTCGTGAAACACGTGGGATA UP region_F 









UP region_R with 3' homology to LV3 
MD258 GGCTGAACAACAGTCTCTCC UP region_F 




DOWN region_F with 5' homology to LV5 
106a 








DOWN region_F with 5' homology to LV5 






















Figure A1. Initial phylogenetic tree of G10H variants 
Initial bootstrapped maximum likelihood phylogenetic tree of potential G10H candidates using the CrG10H as the 



















Figure A2. Identification of conserved cytochrome p450 structural domains for the G10H variants. 
The G10H candidate list was assessed for their inclusion of the structural conservation normally found in the core of 
the protein around the heme. The absolutely conserved cysteine residue of the heme binding loop is shown in red in 



















Figure A3. Identification of neric acid in S. cerevisiae strains expressing CrG10H(Nt)-GrG10H. 
Total ion abundance for A) full length GrG10H and B) CrG10H(Nt)-GrG10H strains extracted from culture broths. Peak 
identification using analytic standards are as follows: 1. Citronellol; 2. Geraniol; 3. Eugenol (internal standard); 4. 















































Figure A4. Monoterpene production from S. cerevisiae strains expressing 3x-CrG10H with different CPRs.  
Sr1CPR was included as it had a similar percent molar conversion as the CrCPR strain. Geraniol (grey) and 10HG 
(pink) titers are reported non-OD600 normalized and were quantified at 24,48 and 72 hours.  Error bars represent the 

























Figure A5. Isopulegol production from engineered S. cerevisiae strains expressing G10H variants. 
A) Isopulegol titers from the full-length G10H variant library. B) Isopulegol titers from the N-terminally modified 

















Figure A6. Isopulegol titers from S. cerevisiae strains expressing 1x- and 3x- CrG10H with different CPRs. 
Geraniol (grey), 10HG (pink) and isopulegol (light pink) production in A) 1x-CrG10H and B) 3x-CrG10H strains. 
Due to lack of an appropriate standard, isopulegol is reported as area under the curve on the right axis and 
normalized to OD600 of 1. Error bars represent the standard deviation across experimental triplicates. 
 
